

CITATION REPORT

List of articles citing

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

DOI: 10.1001/jama.288.19.2421

JAMA - Journal of the American Medical Association, 2002, 288, 2421-31.

Source: <https://exaly.com/paper-pdf/33806401/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1579	Cladribine successful in leukaemia cutis. 2002 , &NA,, 15		
1578	Renal insufficiency as a predictor of adverse events and mortality after renal artery stent placement. 2003 , 42, 926-35		80
1577	[Remission of chronic kidney diseases. A realistic goal?]. 2003 , 115, 405-6		1
1576	[Sympathetic overactivity and the kidney]. 2003 , 115, 634-40		3
1575	Are low target blood pressure goals justified in persons with diabetes mellitus?. <i>Current Hypertension Reports</i> , 2003 , 5, 231-8	4.7	1
1574	Has the role of calcium channel blockers in treating hypertension finally been defined?. <i>Current Hypertension Reports</i> , 2003 , 5, 295-300	4.7	1
1573	Use of calcium antagonists in renal patients: therapeutic benefit or medical malpractice?. <i>Current Hypertension Reports</i> , 2003 , 5, 430-6	4.7	1
1572	[Differentiation and evaluation of calcium antagonists in therapy of arterial hypertension]. 2003 , 44, 483-90		0
1571	AMGEN International Prize: the history and future of renoprotection. 2003 , 64, 1163-8		14
1570	Hypertensive nephrosclerosis in African Americans. 2003 , 64, 2331-41		20
1569	Retarding the progression of renal disease. 2003 , 64, 370-8		43
1568	ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial. 2003 , S74-6		21
1567	Systolic hypertension in hemodialysis patients. 2003 , 16, 208-13		25
1566	Repeated measures of blood pressure and correlations between systolic pressure, pulse pressure and LV mass: a circular debate?. 2003 , 17, 219-21		2
1565	The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALL predictable, and no big surprise out of a HAT?. 2003 , 17, 367-72		3
1564	The new hypertension guidelines from JNC 7: is the devil in the details?. 2003 , 78, 1078-81		2
1563	Despu� del estudio ALLHAT, �qu�abemos de lo que desconoc�mos sobre el tratamiento de la hipertensi� arterial?. 2003 , 56, 642-648		

1562	Outcome studies in diabetic nephropathy. 2003 , 23, 255-71		16
1561	Lacidipine: a review of its use in the management of hypertension. 2003 , 63, 2327-56		43
1560	Meeting the challenge to improve the treatment of hypertension in blacks. <i>Journal of Clinical Hypertension</i> , 2003 , 5, 393-401	2.3	14
1559	The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?. <i>Journal of Clinical Hypertension</i> , 2003 , 5, 159-67	2.3	22
1558	Optimal treatment of hypertension and cardiovascular risk reduction in African Americans: treatment approaches for outpatients. <i>Journal of Clinical Hypertension</i> , 2003 , 5, 18-25	2.3	5
1557	Rationale for combination therapy as initial treatment for hypertension. <i>Journal of Clinical Hypertension</i> , 2003 , 5, 4-11	2.3	15
1556	Creating a combination antihypertensive regimen: what does the research show?. <i>Journal of Clinical Hypertension</i> , 2003 , 5, 12-20	2.3	19
1555	Who should be treated with combination therapy as initial treatment for hypertension?. <i>Journal of Clinical Hypertension</i> , 2003 , 5, 21-8	2.3	3
1554	The first hypertension trial comparing the effects of two fixed-dose combination therapy regimens on cardiovascular events: Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH). <i>Journal of Clinical Hypertension</i> , 2003 , 5, 29-35	2.3	23
1553	What's new in Renal Medicine. 2003 , 31, 1-4		1
1552	Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. 2003 , 362, 1527-35		1958
1551	Registration of trials and protocols. 2003 , 362, 1009-10		7
1550	Preventing renal dysfunction in patients with hypertension: clinical implications from the early AASK Trial results. 2003 , 3, 193-200		1
1549	Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. <i>Hypertension</i> , 2003 , 42, 1206-52	8.5	10207
1548	The Endocrine Society Meeting: topics in insulin sensitivity and hypertension. 2003 , 26, 2679-88		2
1547	Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 2618-22	12.7	144
1546	The contribution of increased diabetes prevalence and improved myocardial infarction and stroke survival to the increase in treated end-stage renal disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 1568-77	12.7	70
1545	The rationale and design of the AASK cohort study. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, S166-72	12.7	78

1544	Blood pressure predicts risk of developing end-stage renal disease in men and women. <i>Hypertension</i> , 2003 , 41, 1341-5	8.5	219
1543	Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 2934-41	12.7	367
1542	Antihypertensive therapy in chronic renal disease: a place for sympatholytic agents?. <i>Journal of Hypertension</i> , 2003 , 21, 1625-6	1.9	2
1541	Comments on the renal aspects of the ALLHAT study. <i>Journal of Hypertension</i> , 2003 , 21, 235-6	1.9	3
1540	Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. <i>Journal of Hypertension</i> , 2003 , 21, 1055-76	1.9	365
1539	Update on calcium antagonists and the kidney. 2003 , 12, 309-15		6
1538	New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk patients with hypertension. <i>Journal of Hypertension</i> , 2003 , 21, 1599-608	1.9	26
1537	What is normal blood pressure?. 2003 , 12, 285-92		18
1536	Recommendations for prevention, diagnosis and management of hypertension and cardiovascular risk factors in sub-Saharan Africa. <i>Journal of Hypertension</i> , 2003 , 21, 1993-2000	1.9	70
1535	Selection of initial antihypertensive therapy, regimen design, and goal blood pressure. 2003 , 11, 197-205		
1534	Emerging drugs for renal failure. 2003 , 8, 389-435		10
1533	Authors' response. <i>Journal of Clinical Hypertension</i> , 2003 , 5, 424-424	2.3	
1532	Best practice of hypertensive patients with kidney disease. 2003 , 64, 96-100		
1531	Trends in blood pressure control in hypertensive patients with diabetes mellitus in Japan. 2003 , 26, 717-22		12
1530	Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. 2004 , 27, 379-85		50
1529	Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy. 2004 , 24, 543-8		42
1528	Hypertensive therapy: Part II. 2004 , 109, 3081-8		28
1527	Surrogate markers for cardiovascular disease: functional markers. 2004 , 109, IV31-46		167

1526	Urinary potassium excretion and sodium sensitivity in blacks. <i>Hypertension</i> , 2004 , 43, 707-13	8.5	96
1525	Pathophysiology of hypertensive renal damage: implications for therapy. <i>Hypertension</i> , 2004 , 44, 595-608	8.5	243
1524	Calcium channel blockers in the prevention of end stage renal disease: a review. 2004 , 59, 44-56		9
1523	New European guidelines for management of hypertension: what is relevant for the nephrologist. 2004 , 19, 524-8		0
1522	The prevalence of and risk factors for hypertension in adults living in Istanbul. 2004 , 13, 31-6		21
1521	Trends in incidence of end-stage renal disease in Japan, 1983-2000: age-adjusted and age-specific rates by gender and cause. 2004 , 19, 2044-52		58
1520	Varicella zoster virus: vaccination and implications in children with renal failure. 2004 , 3, 291-8		12
1519	Sodium glomerulopathy: tubuloglomerular feedback and renal injury in African Americans. 2004 , 65, 361-8		45
1518	Differential effects of calcium antagonist subclasses on markers of nephropathy progression. 2004 , 65, 1991-2002		156
1517	Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. 2004 , S45-9		34
1516	Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). 2004 , S90-6		50
1515	Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. 2004 , S99-101		37
1514	Proteinuria and hypertensive nephrosclerosis in African Americans. 2004 , S102-4		21
1513	Inclusion of albuminuria in hypertension and heart guidelines. 2004 , S124-5		7
1512	Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. 2004 , 18, 139-85		868
1511	Calcium antagonists. 2004 , 47, 34-57		93
1510	Achievement of target blood pressure levels in chronic kidney disease: a salty question?. 2004 , 43, 782-95		75
1509	References. 2004 , 43, 268-290		

1508	Optimizing hypertension and vascular health: focus on ethnicity. 2004 , 6, 28-38		8
1507	Research review: hypertension management in African Americans. 2004 , 25, 60-1		
1506	Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both?. 2004 , 19, 956-61		36
1505	The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy. 2004 , 47, 98-103		35
1504	Antihypertensive drugs and the kidney. 2004 , 6, 403-8		3
1503	Hypertension in black patients: special issues and considerations. 2004 , 6, 416-20		11
1502	Combination drug treatment of hypertension: have we come full circle?. 2004 , 6, 421-6		19
1501	Hypertension management: special considerations in chronic kidney disease patients. <i>Current Hypertension Reports</i> , 2004 , 6, 462-8	4-7	5
1500	Clinical importance of microalbuminuria in diabetes and hypertension. <i>Current Hypertension Reports</i> , 2004 , 6, 352-6	4-7	37
1499	Blood pressure and progression of chronic kidney disease: importance of systolic, diastolic, or diurnal variation. <i>Current Hypertension Reports</i> , 2004 , 6, 400-4	4-7	12
1498	Is proteinuria a plausible target of therapy?. <i>Current Hypertension Reports</i> , 2004 , 6, 177-81	4-7	21
1497	Hypertensive renal damage: insights from animal models and clinical relevance. <i>Current Hypertension Reports</i> , 2004 , 6, 145-53	4-7	38
1496	ESH/ESC Hypertension Guidelines. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2004 , 11, 9-10	2-9	
1495	Nouvelles recommandations américaines : analyse critique. 2004 , 4, 7-11		1
1494	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. 2004 , 24, 168-75		56
1493	Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies. 2004 , 24, 158-67		32
1492	[Relevance of chronic kidney disease and cardiovascular prognosis in arterial hypertension]. 2004 , 123, 143-8		1
1491	Chronic renal insufficiency and cardiovascular events in the elderly: findings from the Cardiovascular Health Study. 2004 , 13, 81-90		40

1490	The prevention of heart failure in minority communities and discrepancies in health care delivery systems. <i>Medical Clinics of North America</i> , 2004 , 88, 1347-68, xii-xiii	7	17
1489	What have we learned from the current trials?. <i>Medical Clinics of North America</i> , 2004 , 88, 189-207	7	20
1488	Pharmacological strategies for kidney function preservation: are there differences by ethnicity?. 2004 , 11, 24-40		10
1487	Cardiovascular risk reduction and preservation of renal function in the early nephropathy patient. 2004 , 11, 184-91		2
1486	Hypertension. 2004 , 44, 369-75		0
1485	Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. 2004 , 43, 1047-55		100
1484	Relationships of race and ethnicity to progression of kidney dysfunction and clinical outcomes in patients with chronic kidney failure. 2004 , 11, 14-23		23
1483	Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. 2004 , 147, 331-8		391
1482	Slowing the progression of diabetic nephropathy and its cardiovascular consequences. 2004 , 148, 243-51		25
1481	The importance of blood pressure control in the patient with diabetes. <i>American Journal of Medicine</i> , 2004 , 116 Suppl 5A, 30S-38S	2.4	75
1480	The case for diversity in academic internal medicine. <i>American Journal of Medicine</i> , 2004 , 116, 284-9	2.4	27
1479	Recruitment of African Americans with chronic renal insufficiency into a multicenter clinical trial: the african american study of kidney disease and hypertension. <i>Journal of Clinical Hypertension</i> , 2004 , 6, 430-6	2.3	4
1478	The disproportionate impact of hypertensive cardiovascular disease in African Americans: getting to the heart of the issue. <i>Journal of Clinical Hypertension</i> , 2004 , 6, 4-10	2.3	32
1477	Managing hypertension in African-American patients. <i>Journal of Clinical Hypertension</i> , 2004 , 6, 19-25	2.3	7
1476	Hypertension control among African Americans: an urgent call for action. <i>Journal of Clinical Hypertension</i> , 2004 , 6, 333-4	2.3	2
1475	Implications of albuminuria on kidney disease progression. <i>Journal of Clinical Hypertension</i> , 2004 , 6, 18-22.3		11
1474	Recommendations for Special Populations. 2004 , 14, 368-381		7
1473	Imidapril improves L-NAME-exacerbated nephrosclerosis with TGF-beta 1 inhibition in spontaneously hypertensive rats. <i>Journal of Hypertension</i> , 2004 , 22, 1389-95	1.9	20

1472	Correspondence. <i>Journal of Hypertension</i> , 2004 , 22, 1048	1.9	
1471	Effects of losartan and chlorthalidone on blood pressure and renal vascular resistance index in non-diabetic patients with essential hypertension and normal renal function. 2004 , 44, 520-4		8
1470	Development of chronic kidney disease in essential hypertension during long-term therapy. 2004 , 13, 495-500		
1469	Hypertensive nephrosclerosis: update. 2004 , 13, 147-54		11
1468	The role of calcium antagonists in chronic kidney disease. 2004 , 13, 155-61		23
1467	ACE inhibitors and target organ protection. An expanded role for these antihypertensive agents?. 2004 , 116, 11-6, 19-22, 48		8
1466	Cigarette smoking enhances increased urine albumin excretion as a risk factor for glomerular filtration rate decline in primary hypertension. 2005 , 330, 111-9		21
1465	Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. 2005 , 329, 292-305		64
1464	Treating hypertension with cardioprotective therapies: the role of ACE inhibitors, ARBs, and beta-blockers. 2005 , 20, 354-64		20
1463	Recent advances in hypertension, stroke, and cardiorenal disease. 2005 , 20, 258-63		7
1462	Thiazide diuretics enhance nocturnal blood pressure fall and reduce proteinuria in immunoglobulin A nephropathy treated with angiotensin II modulators. <i>Journal of Hypertension</i> , 2005 , 23, 861-5	1.9	33
1461	Primary and secondary prevention of chronic kidney disease. <i>Journal of Hypertension</i> , 2005 , 23, 1771-6	1.9	7
1460	Physiologic evidence of renoprotection by antihypertensive therapy. 2005 , 20, 290-5		2
1459	Evidence-based medicine in hypertension: what type of evidence?. <i>Journal of Hypertension</i> , 2005 , 23, 1113-20	1.9	42
1458	WITHDRAWN: Effect of antihypertensive drugs on mortality, morbidity and blood pressure in blacks. 2007 , CD005183		2
1457	Reliability of a medication adherence measure in an outpatient setting. 2005 , 330, 128-33		61
1456	Is ethnicity a factor in choice of antihypertensive drug?. 2005 , 117, 40-40		1
1455	Minor abnormalities of renal function: a situation requiring integrated management of cardiovascular risk. 2005 , 19, 429-37		8

1454	Circulating vitamin E, transforming growth factor beta1, and the association with renal disease susceptibility in two racial groups with type 2 diabetes. 2005 , 67, 1993-8	9
1453	Unraveling the racial disparities associated with kidney disease. 2005 , 68, 914-24	141
1452	Racial and ethnic disparities in renal disease. 2005 , 68, 1364-5	4
1451	Is it the agent or the blood pressure level that matters for renal and vascular protection in chronic nephropathies?. 2005 , S15-9	4
1450	What have we learned from clinical trials on prevention?. 2005 , S101-6	2
1449	Management of early chronic kidney disease in indigenous populations and ethnic minorities. 2005 , S78-81	11
1448	Systemic and glomerular hypertension and progression of chronic renal disease: the dilemma of nephrosclerosis. 2005 , S52-6	46
1447	The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. 2005 , S57-65	306
1446	Clinical benefits of slowing the progression of renal failure. 2005 , S152-6	3
1445	Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan. 2005 , 19, 173-83	20
1444	Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. 2005 , 45, 281-7	257
1443	Long-term deterioration of kidney allograft function. 2005 , 5, 1405-14	99
1442	Amlodipine preserves the glomerular number in spontaneously hypertensive rats. 2005 , 9, 966-71	5
1441	Caring for patients with chronic kidney disease: a joint opinion of the ambulatory care and the nephrology practice and research networks of the American College of Clinical Pharmacy. 2005 , 25, 123-43	17
1440	[Guidelines for therapy of chronic heart failure]. 2005 , 94, 488-509	56
1439	The role of calcium antagonists in patients with chronic renal failure. 2005 , 20, 1208-13	5
1438	The impact of race on response to RAAS inhibition. 2005 , 2, 72-7	5
1437	Hypertension in black patients: special issues and considerations. <i>Current Hypertension Reports</i> , 2005 , 7, 244-8	4-7 21

1436	Can we justify goal blood pressure of . <i>Current Hypertension Reports</i> , 2005 , 7, 257-64	4.7	7
1435	Clinical trials report. <i>Current Hypertension Reports</i> , 2005 , 7, 437-438	4.7	1
1434	Does ALLHAT change the management of hypertension in chronic kidney disease?. <i>Current Hypertension Reports</i> , 2005 , 7, 474-83	4.7	4
1433	Treatment of resistant hypertension. <i>Current Hypertension Reports</i> , 2005 , 7, 323-9	4.7	23
1432	Combination Drug Treatment for Hypertension. <i>Current Hypertension Reports</i> , 2005 , 7, 358-359	4.7	2
1431	Should the target for blood pressure control specify both a systolic and a diastolic component?. <i>Current Hypertension Reports</i> , 2005 , 7, 360-2	4.7	5
1430	The African American Study of Kidney Disease: do these results indicate that 140/90 mm hg is good enough?. <i>Current Hypertension Reports</i> , 2005 , 7, 363-6	4.7	2
1429	Antihypertensive, antiproteinuric therapy and myocardial infarction and stroke prevention. <i>Current Hypertension Reports</i> , 2005 , 7, 367-73	4.7	4
1428	Proteinuria reduction: mandatory consideration or option when selecting an antihypertensive agent?. <i>Current Hypertension Reports</i> , 2005 , 7, 374-8	4.7	11
1427	ACE Inhibitor Trials: Effects in Hypertension. 2005 , 386-390		
1426	Calcium channel blockers and renal protection: insights from the latest clinical trials. <i>Journal of the American Society of Nephrology: JASN</i> , 2005 , 16 Suppl 1, S64-6	12.7	18
1425	Calcium antagonists: effects on cardio-renal risk in hypertensive patients. <i>Hypertension</i> , 2005 , 46, 637-428.5		56
1424	Should ethnicity serve as the basis for clinical trial design? Importance of race/ethnicity in clinical trials: lessons from the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 2005 , 112, 3654-60; discussion 3666		62
1423	Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. <i>Hypertension</i> , 2005 , 45, 907-13	8.5	211
1422	Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. 2005 , 112, 969-75		563
1421	Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2005 , 16, 2170-9	12.7	249
1420	Control of hypertension in adults with chronic kidney disease in the United States. <i>Hypertension</i> , 2005 , 45, 1119-24	8.5	126
1419	Hypertension 2005: an evidence-based approach to diagnosis and treatment - an American perspective. 2005 , 3, 691-704		4

1418	Major clinical trials of hypertension: what should be done next?. <i>Hypertension</i> , 2005 , 46, 1-6	8.5	92
1417	Blood pressure control, drug therapy, and kidney disease. <i>Hypertension</i> , 2005 , 46, 44-50	8.5	26
1416	Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. <i>Journal of the American Society of Nephrology: JASN</i> , 2005 , 16 Suppl 1, S58-63	12.7	67
1415	Modest salt reduction reduces blood pressure and urine protein excretion in black hypertensives: a randomized control trial. <i>Hypertension</i> , 2005 , 46, 308-12	8.5	127
1414	Renal protective effects of the renin-angiotensin-aldosterone system blockade: from evidence-based approach to perspectives. 2005 , 28, 230-42		27
1413	Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. 2005 , 112, 171-8		161
1412	Blood pressure control is hard to achieve in patients with chronic renal failure: results from a survey of renal units in Norway. 2005 , 39, 242-8		5
1411	Diabetic nephropathy: the proteinuria hypothesis. 2005 , 25, 77-94		72
1410	Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: executive summary. 2005 , 111, 1339-49		51
1409	Zenon's paradox or how much to lower blood pressure for optimal renoprotection. 2005 , 20, 2304-7		3
1408	Racial variations in erythropoietic response to epoetin alfa in chronic kidney disease and the impact of smoking. 2005 , 20, 2739-45		8
1407	Chronic kidney disease: the global challenge. 2005 , 365, 331-40		684
1406	Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. 2005 , 365, 939-46		471
1405	¿Cuáles el impacto del control estricto de la presión arterial sobre la progresión de la enfermedad renal?. 2005 , 12, 430		
1404	Hypertension and atherosclerosis: clinical implications from the ALLHAT Trial. 2005 , 7, 132-9		12
1403	Strategies to retard the progression of chronic kidney disease. <i>Medical Clinics of North America</i> , 2005 , 89, 489-509	7	23
1402	Hypertension in chronic kidney disease and dialysis: pathophysiology and management. 2005 , 23, 237-48		24
1401	Drug dosing in chronic kidney disease. <i>Medical Clinics of North America</i> , 2005 , 89, 649-87	7	60

1400	Hypertension treatment guidelines: practical implications. 2005 , 25, 198-209		8
1399	Hypertension and the kidney. 2005 , 25, 236-45		16
1398	Clinical guidelines for the treatment of hypertension in African Americans. 2005 , 5, 1-6		27
1397	Industry Pulse. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2005 , 12, 109-114		2.9
1396	JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. 2005 , 91 Suppl 5, v1-52		523
1395	Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. <i>Hypertension</i> , 2005 , 46, 1309-15	8.5	64
1394	Management of hypertensive chronic kidney disease: role of calcium channel blockers. <i>Journal of Clinical Hypertension</i> , 2005 , 7, 15-20	2.3	16
1393	Ethnicity and blood pressure. <i>Journal of Clinical Hypertension</i> , 2005 , 7, 357-64	2.3	9
1392	Early initiation of beta blockade in heart failure: issues and evidence. <i>Journal of Clinical Hypertension</i> , 2005 , 7, 520-8; quiz 529-30	2.3	6
1391	Treating stage 2 hypertension. <i>Journal of Clinical Hypertension</i> , 2005 , 7, 464-70	2.3	3
1390	Ethnic differences in the treatment and control of hypertension in patients with diabetes. <i>Journal of Clinical Hypertension</i> , 2005 , 7, 445-54	2.3	15
1389	Therapeutic considerations in the African-American patient with hypertension: considerations with calcium channel blocker therapy. <i>Journal of Clinical Hypertension</i> , 2005 , 7, 9-14	2.3	8
1388	Calcium channel blockers: a more expansive treatment role. <i>Journal of Clinical Hypertension</i> , 2005 , 7, 2-4	2.3	4
1387	Hypertension: a review and rationale of treatment. 2005 , 51, 548-614		8
1386	Nephroangiosclerosis. 2005 , 2, 103-124		
1385	Update on the drug treatment of hypertension in patients with cardiovascular disease. <i>American Journal of Medicine</i> , 2005 , 118, 695-705	2.4	21
1384	Progression of chronic kidney disease: can it be prevented or arrested?. <i>American Journal of Medicine</i> , 2005 , 118, 1323-30	2.4	47
1383	Dietary protein intake and renal function. 2005 , 2, 25		158

1382	Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. 2005 , 28, 385-407	209
1381	Epidemiology and risk factors for chronic kidney disease. <i>Medical Clinics of North America</i> , 2005 , 89, 419-45	54
1380	Recent hypertension trials: implications and controversies. 2005 , 45, 813-27	95
1379	Néphropathie diabétique et traitement antihypertenseur : quelles sont les leçons des essais cliniques ?. 2005 , 2, 182-193	
1378	Treatment of hypertension in chronic kidney disease. 2005 , 25, 435-9	68
1377	Clinical pharmacology of antihypertensive therapy. 2005 , 25, 215-26	6
1376	Renal protection in hypertensive patients: selection of antihypertensive therapy. 2005 , 65 Suppl 2, 29-39	46
1375	Potential side effects of renin inhibitors--mechanisms based on comparison with other renin-angiotensin blockers. 2006 , 5, 631-41	20
1374	Critical Considerations in Drug Development in Ethnically Diverse Populations. 2006 , 20, 311-316	
1373	[Hypertension in blacks]. 2006 , 35, 1067-71	2
1372	Tratamiento de la hipertensión arterial. 2006 , 23, 298-312	1
1371	Beta blockers for the treatment of primary hypertension. 2006 , 367, 208; author reply 210	5
1370	Blockers for the treatment of primary hypertension [Authors' reply. 2006 , 367, 210	
1369	What is the role of angiotensin-receptor blockade in cardiovascular protection?. 2006 , 152, 859.e1-8	4
1368	Bariatric surgery for morbid obesity: risks and benefits in chronic kidney disease patients. 2006 , 13, 403-17	13
1367	Albuminuria and cardiovascular risk. 2006 , 2, 53-9	2
1366	Tratamiento de la hipertensión arterial. 2006 , 23, 298-312	
1365	Microalbuminuria. 2006 , 26, 635-53, vi-vii	42

1364	A primer on the design, conduct, and interpretation of clinical trials. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006 , 1, 1360-7	6.9	19
1363	Calcium channel blockers in the spectrum of antihypertensive agents. 2006 , 7, 2385-401		8
1362	Racial differences are seen in blood pressure response to fosinopril in hypertensive children. 2006 , 152, 394-9		30
1361	Hypertension and kidney damage. <i>Journal of Clinical Hypertension</i> , 2006 , 8, 209-14	2.3	13
1360	Target blood pressure in patients with end-stage renal disease: evidence-based medicine or the emperor's new clothes?. <i>Journal of Clinical Hypertension</i> , 2006 , 8, 369-75	2.3	2
1359	Hypertension-related morbidity and mortality in African Americans--why we need to do better. <i>Journal of Clinical Hypertension</i> , 2006 , 8, 21-30	2.3	43
1358	Achieving blood pressure goals: why aren't we?. <i>Journal of Clinical Hypertension</i> , 2006 , 8, 865-72	2.3	37
1357	Incidence and Characteristics of Angioedema Associated With Enalapril. 2006 , 2006, 80-81		
1356	Hypertension artifielle essentielle et rein. 2006 , 1, 1-17		
1355	The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-term Follow-up of the Modification of Diet in Renal Disease Study. 2006 , 2006, 74-76		
1354	Blood-Pressure Control for Renoprotection in Patients With Nondiabetic Chronic Renal Disease (REIN-2): Multicentre, Randomised Controlled Trial. 2006 , 2006, 76-78		
1353	Diagnostic, facteurs de risque et traitement de l'insuffisance rBale chronique de l'adulte. 2006 , 1, 1-15		
1352	Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials. <i>Journal of Hypertension</i> , 2006 , 24, S19-27	1.9	10
1351	Primary hypertension and nephropathy. 2006 , 15, 130-4		19
1350	Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. 2006 , 21, 2133-43		108
1349	Improving outcomes in renal disease. 2006 , 19, 20-5		4
1348	The Role of Calcium Antagonists in the Treatment of Hypertension in Patients With Diabetes. 2006 , 16, 349-357		1
1347	Ethnicity and socio-economic inequalities in malignant hypertension. <i>Journal of Hypertension</i> , 2006 , 24, 2161-2	1.9	

1346	How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. <i>Journal of Hypertension</i> , 2006 , 24, 2131-41	1.9	103
1345	Cardiovascular complications after renal transplantation and their prevention. 2006 , 82, 603-11		295
1344	Which drug should be used to treat patients with uncomplicated essential hypertension?. 2006 , 15, 303-8		2
1343	Diuretics: a modern day treatment option?. 2006 , 11, 419-27		12
1342	Blood pressure control: targets. 2006 , 11, S55-S59		
1341	Blood pressure control: role of specific antihypertensives. 2006 , 11, S60-S65		
1340	Overutilization of central venous catheters in incident hemodialysis patients: reasons and potential resolution strategies. 2006 , 19, 543-50		19
1339	Japanese Society of Hypertension. 2006 , 29, S1-S105		29
1338	RAS inhibition in hypertension. 2006 , 20, 101-8		78
1337	Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. 2006 , 20, 239-53		43
1336	Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial. 2006 , 20, 693-700		4
1335	'Hypertension' and 'microalbuminuria': the bell tolls for thee. 2006 , 69, 22-8		52
1334	Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease. 2006 , 69, 406-11		133
1333	Progression of kidney dysfunction in the community-dwelling elderly. 2006 , 69, 2155-61		252
1332	Hypertensive nephrosclerosis. 2006 , 70, 1383; author reply 1383-4		2
1331	Response to Hypertensive nephrosclerosis: Pathogenesis and prevalence□ 2006 , 70, 1383-1384		
1330	Predicting initiation and progression of chronic kidney disease: Developing renal risk scores. 2006 , 70, 1694-705		161
1329	Beta blockers in the management of chronic kidney disease. 2006 , 70, 1905-13		134

1328	Proposal for mapping renal failure in Japan and its application for strategy to arrest endstage renal disease. 2006 , 10, 8-12		7
1327	[Sequelae of hypertenson: kidney disease]. 2006 , 47, 226, 228-32		0
1326	Lessons from the African-American Study of Kidney Disease and Hypertension: an update. <i>Current Hypertension Reports</i> , 2006 , 8, 409-12	4-7	17
1325	Predictors of chronic kidney disease in long-term survivors of lung and heart-lung transplantation. 2006 , 6, 2157-63		46
1324	Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. 2006 , 47, 751-60		140
1323	Surrogate markers in clinical studies: problems solved or created?. 2006 , 48, 159-66		36
1322	Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. 2006 , 48, 739-51		109
1321	Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. 2006 , 48, 879-88		115
1320	Beta-blockers for primary prevention in hypertension: era bygone?. 2006 , 49, 76-87		10
1319	Mechanisms of target organ damage caused by hypertension: therapeutic potential. 2006 , 111, 81-98		103
1318	The metabolic syndrome and cardiometabolic risk: scope of the problem and current standard of care. 2006 , 26, 3S-12S		13
1317	Randomized, double-blind, crossover comparison of amlodipine and valsartan in african-americans with hypertension using 24-hour ambulatory blood pressure monitoring. 2006 , 26, 889-95		4
1316	Angiotensin II formation in the kidney and nephrosclerosis in Ren-2 hypertensive rats. 2006 , 21, 1778-85		25
1315	Which target blood pressure is optimal for renoprotection?. 2006 , 2, 58-9		
1314	Clinic versus home blood-pressure measurements as a predictor of outcomes in chronic kidney disease. 2006 , 2, 474-5		
1313	Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease. 2006 , 26, 503-10		91
1312	Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. 2006 , 174, 1737-42		148
1311	Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 1444-52	12.7	206

1310	Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 3472-81	12.7	54
1309	Opening words for CJASN. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006 , 1, 3-5	6.9	1
1308	Clinical Research Methods in CJASN. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006 , 1, 1115-1116	6.9	1
1307	The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. 2006 , 114, 2871-91		93
1306	The chronic kidney disease epidemic: stepping back and looking forward. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 2967-73	12.7	49
1305	Validation of creatinine-based estimates of GFR when evaluating risk factors in longitudinal studies of kidney disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 2900-9	12.7	57
1304	Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 2928-36	12.7	115
1303	Kidney-heart interactions: epidemiology, pathogenesis, and treatment. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006 , 1, 8-18	6.9	133
1302	Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. <i>Hypertension</i> , 2006 , 48, 374-84	8.5	128
1301	Unexpected role of TRPC6 channel in familial nephrotic syndrome: does it have clinical implications?. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 378-87	12.7	35
1300	More work to do on renin-angiotensin system blockade. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006 , 1, 611-3	6.9	2
1299	Antiproteinuric effect of losartan in non-diabetic renal disease is not dependent on ACE insertion/deletion polymorphism. 2006 , 29, 216-24		8
1298	Lessons learned from recent hypertension trials about kidney disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006 , 1, 229-35	6.9	31
1297	Pharmacological management of renal fibrotic disease. 2006 , 7, 377-86		3
1296	Changing relationship of blood pressure with mortality over time among hemodialysis patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 513-20	12.7	112
1295	Does the hyperfiltration of minoxidil result in increased proteinuria and loss of renoprotection conferred by angiotensin inhibition?. 2006 , 29, 54-9		2
1294	New Generation Calcium Channel Blockers in Hypertensive Treatment. 2006 , 2, 103-111		23
1293	Surrogate end points for clinical trials of kidney disease progression. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006 , 1, 874-84	6.9	98

1292	Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006 , 1, 1006-15	6.9	259
1291	Blood pressure reduction is not the only determinant of outcome. 2006 , 113, 2754-72; discussion 2773-4		60
1290	Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006 , 1, 1054-65	6.9	77
1289	Rationale and public health implications of changing CHD risk factor definitions. 2007 , 28, 321-44		24
1288	Hypertension. 2007 ,		
1287	Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2007 , 18, 1518-6	12.7	225
1286	Chronic kidney disease after nonrenal solid-organ transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2007 , 18, 3031-41	12.7	138
1285	The kidney and cardiovascular risk—implications for management: a consensus statement from the European Society of Hypertension. 2007 , 16, 72-9		20
1284	Calcium channels blockers and progression of kidney disease. 2007 , 29, 1003-12		3
1283	Albuminuria reduction: the holy grail for kidney protection. 2007 , 72, 785-6		2
1282	Improvement of blood pressure control in hypertensive patients with renal diseases. 2007 , 30, 295-300		1
1281	Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria. 2007 , 30, 39-47		6
1280	Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. 2007 , 115, 2761-88		557
1279	Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review. 2007 , 5, 444-52		53
1278	Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. <i>Journal of Hypertension</i> , 2007 , 25, 951-8	1.9	325
1277	REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease. <i>Hypertension</i> , 2007 , 50,	8.5	13
1276	Prevalence of chronic kidney disease and survival among aboriginal people. <i>Journal of the American Society of Nephrology: JASN</i> , 2007 , 18, 2953-9	12.7	71
1275	Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. <i>Hypertension</i> , 2007 , 50, 299-305	8.5	142

1274	Beta-blockers for hypertension. 2007 , CD002003		111
1273	Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. <i>Journal of Hypertension</i> , 2007 , 25, 2082-92	1.9	37
1272	The management of hypertension in African Americans. 2007 , 6, 67-71		63
1271	Clinical trials in nephrology: success or failure. 2007 , 16, 59-63		6
1270	'Beyond blood pressure' means multiple risk factor intervention, not pleiotropic antihypertensive drugs. 2007 , 22, 335-43		9
1269	Are differences in calcium antagonists relevant across all stages of nephropathy or only proteinuric nephropathy?. 2007 , 16, 422-6		3
1268	Hypertension associ� aux st�fioses de l'art�re r�biale et aux atteintes r�biales parenchymateuses. 2007 , 2, 1-28		0
1267	Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. 2007 , 2007, 96-99		
1266	Hypertension and the kidney. 2007 , 62, 5-14		10
1265	Resistant hypertension: prevalence and evolving concepts. <i>Journal of Clinical Hypertension</i> , 2007 , 9, 2-6	2.3	29
1264	Kidney disease, Framingham risk scores, and cardiac and mortality outcomes. <i>American Journal of Medicine</i> , 2007 , 120, 552.e1-8	2.4	30
1263	[Which optimal antihypertensive bitherapy for kidney patients?]. 2007 , 3, 79-88		
1262	Hipertensi�n arterial y ri�n. 2007 , 9, 5266-5271		
1261	Treatment of hypertension in patients with nondiabetic chronic kidney disease. 2007 , 23, 595-601		7
1260	2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 , 16, 135-232		247
1259	Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. 2007 , 72, 1543-9		110
1258	Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. 2007 , 72, 879-85		77
1257	Applying hypertension guidelines to reduce the burden of heart failure. 2007 , 25, 507-22; v-vi		3

1256	Cardiovascular disease posttransplant. 2007 , 27, 430-44	30
1255	Should beta-blockers be used to control hypertension in people with chronic kidney disease?. 2007 , 27, 555-64	28
1254	[ESH/ESC 2007 Guidelines for the management of arterial hypertension]. 2007 , 60, 968.e1-94	29
1253	[Prevalence of low glomerular filtration rate in the elderly population of Spain. The PREV-ICTUS study]. 2007 , 129, 681-7	9
1252	Dihydropyridine calcium channel antagonists in the management of hypertension. 2007 , 67, 1309-27	77
1251	Proteinuria. 2007 , 793-800	
1250	Renal Dysfunction in Hypertension and Obesity. 2007 , 575-595	2
1249	Angiotensin-Converting Enzyme Inhibitors. 2007 , 985-1001	
1248	Calcium Antagonists. 2007 , 971-983	
1247	Hypertension in African Americans. 2007 , 468-481	
1246	Calcium Channel Blockers in Hypertension. 2007 , 268-285	
1245	Target Blood Pressure in Hypertension Treatment: The J-shaped Curve Controversy. 2007 , 1113-1118	
1244	Racial and ethnic disparities in end-stage kidney failure-survival paradoxes in African-Americans. 2007 , 20, 577-85	72
1243	AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. 2007 , 11, 189-95	68
1242	Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuff. 2007 , 27, 1322-33	7
1241	Systemic hypertension. 2007 , 32, 201-59	54
1240	Anemia as a risk factor for kidney function decline in individuals with heart failure. 2007 , 99, 1137-42	36
1239	Combination therapy with an angiotensin-converting enzyme inhibitor and a calcium channel blocker. <i>Journal of Clinical Hypertension</i> , 2007 , 9, 783-9	2.3 10

1238	Antihypertensive therapy in the presence of proteinuria. 2007 , 49, 12-26		475
1237	Baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Clinical Trial and Cohort Study. 2007 , 50, 78-89, 89.e1		37
1236	Impact of creatinine calibration on performance of GFR estimating equations in a pooled individual patient database. 2007 , 50, 21-35		163
1235	Efectos pleiotrpicos de telmisartn en el paciente diabtico. 2007 , 7, 23A-30A		
1234	Systemic Hypertension [Newer Guidelines. 2007 , 4, 189-196		
1233	Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system. 2007 , 24, 1290-304		17
1232	Hypertension and kidney protection in the elderly: what is the evidence in 2007?. 2007 , 39, 669-78		8
1231	Description of pharmacist interventions during physician-pharmacist co-management of hypertension. 2008 , 30, 128-35		57
1230	The association of anemia and hypoalbuminemia with accelerated decline in GFR among adolescents with chronic kidney disease. 2007 , 22, 265-71		43
1229	Low-grade albuminuria and cardiovascular risk : what is the evidence?. 2007 , 96, 247-57		84
1228	Renal protection: are all antihypertensive drugs comparable?. <i>Current Hypertension Reports</i> , 2007 , 9, 373-9	4-7	4
1227	Dual effects of RAS blockade on blood pressure and podocyte function. <i>Current Hypertension Reports</i> , 2007 , 9, 403-8	4-7	34
1226	Do beta-blockers combined with RAS inhibitors make sense after all to protect against renal injury?. <i>Current Hypertension Reports</i> , 2007 , 9, 409-14	4-7	7
1225	Race-based therapeutics. 2007 , 1, 108-117		
1224	Combating racial and ethnic disparities in cardiovascular disease: What is being done?. 2007 , 1, 124-132		
1223	Patient complexity: more than comorbidity. the vector model of complexity. 2007 , 22 Suppl 3, 382-90		199
1222	Inhibition of the renin-angiotensin system and chronic kidney disease. 2008 , 40, 1015-25		19
1221	Potential risks of calcium channel blockers in chronic kidney disease. 2008 , 10, 448-55		10

1220	Evidence for benefits of angiotensin receptor blockade beyond blood pressure control. <i>Current Hypertension Reports</i> , 2008 , 10, 261-7	4-7	27
1219	Race-based therapeutics. <i>Current Hypertension Reports</i> , 2008 , 10, 276-85	4-7	15
1218	[Hypertension and the kidney]. 2008 , 158, 359-64		1
1217	Slowing chronic kidney disease progression: results of prospective clinical trials in adults. 2008 , 23, 1409-22		3
1216	Therapeutic strategies to slow chronic kidney disease progression. 2008 , 23, 705-16		61
1215	Current and future status of beta-blockers in the treatment of hypertension. 2008 , 31, 249-52		24
1214	MYH9 is associated with nondiabetic end-stage renal disease in African Americans. 2008 , 40, 1185-92		518
1213	Cost-effectiveness of the oral adsorbent AST-120 versus placebo for chronic kidney disease. 2008 , 13, 419-27		6
1212	Race and end-stage renal disease in the United States Medicare population: the disparity persists. 2008 , 13, 651-6		7
1211	Economic burden of chronic kidney disease. 2008 , 14, 422-34		48
1210	Physician adherence to blood pressure guidelines and its effect on seniors. 2008 , 28, 843-51		23
1209	Reduction in adverse symptoms as blood pressure becomes controlled. 2008 , 28, 1104-14		9
1208	Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. 2008 , 51, 395-406		819
1207	Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy. <i>Journal of Clinical Hypertension</i> , 2008 , 10, 761-9	2-3	14
1206	Evaluation and treatment of resistant or difficult-to-control hypertension. <i>Journal of Clinical Hypertension</i> , 2008 , 10, 837-43	2-3	11
1205	State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. <i>Journal of Clinical Hypertension</i> , 2008 , 10, 130-9	2-3	78
1204	A cluster randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control. <i>Journal of Clinical Hypertension</i> , 2008 , 10, 260-71	2-3	155
1203	The kidney and hypertension: causes and treatment. <i>Journal of Clinical Hypertension</i> , 2008 , 10, 541-8	2-3	7

1202	ONTARGET: questions asked, questions answered. <i>Journal of Clinical Hypertension</i> , 2008 , 10, 427-30	2.3	
1201	Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. 2008 , 22, 303-8		16
1200	Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both. 2008 , 51, 1865-71		12
1199	Mechanisms and management of proteinuria in kidney transplant patients. 2008 , 68 Suppl 1, 33-9		11
1198	Blood pressure control in the patient with difficult-to-control hypertension: which agent for which patient?. 2008 , 11, 42-9		3
1197	Risk-based classification of hypertension and the role of combination therapy. <i>Journal of Clinical Hypertension</i> , 2008 , 10, 4-12	2.3	18
1196	Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. <i>American Journal of Hypertension</i> , 2008 , 21, 61-6	2.3	47
1195	Cystatin C concentration as a predictor of systolic and diastolic heart failure. 2008 , 14, 19-26		43
1194	An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study. 2008 , 30, 1618-28		24
1193	An association of a variety of cardiovascular risk factors with low grade albuminuria in Korean men. 2008 , 196, 320-326		13
1192	High dose treatment with angiotensin II receptor blocker in patients with hypertension: differential effect of tissue protection versus blood pressure lowering. 2008 , 197, 303-10		15
1191	Traitement de l'hypertension artérielle. 2008 , 41-71		
1190	Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacy. 2008 , 24, 491-6		32
1189	Nefroprotección. Bloqueo del sistema renina-angiotensina. 2008 , 34, 127-132		
1188	Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. 2008 , 2, 349-54		115
1187	Dihydropyridinic Calcium-Channel Antagonists in the 2007 ESH/ESC Hypertension Guidelines. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008 , 15, 85-90	2.9	
1186	Management of cardiovascular disease in renal transplant recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008 , 3, 491-504	6.9	85
1185	Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. 2008 , 118, 1383-93		143

1184	Race-based therapy for hypertension: possible benefits and potential pitfalls. 2008 , 6, 1357-66		24
1183	High perfusion pressure accelerates renal injury in salt-sensitive hypertension. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 1472-82	12.7	80
1182	Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. 2008 , 29, 2669-80		172
1181	Management and control of hypertension and proteinuria in patients with advanced chronic kidney disease under nephrologist care or not: data from the AVENIR study (AVantagE de la Nephroprotection dans l'Insuffisance Renale). 2009 , 24, 934-9		9
1180	Should nephrologists use beta-blockers? A perspective. 2009 , 24, 701-2		13
1179	Competing risk factor analysis of end-stage renal disease and mortality in chronic kidney disease. 2008 , 28, 569-75		44
1178	Analyzing change: a primer on multilevel models with applications to nephrology. 2008 , 28, 792-801		67
1177	Association analysis of the ephrin-B2 gene in African-Americans with end-stage renal disease. 2008 , 28, 914-20		6
1176	Implications of ethnicity for the treatment of hypertensive kidney disease, with an emphasis on African Americans. 2008 , 4, 538-49		17
1175	Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. <i>Hypertension</i> , 2008 , 51, 1465-7	8.5	42
1174	Slowing nephropathy progression: focus on proteinuria reduction. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008 , 3 Suppl 1, S3-10	6.9	83
1173	Randomized study of traditional versus aggressive systolic blood pressure control (Cardio-Sis): rationale, design and characteristics of the study population. 2008 , 22, 243-51		8
1172	Cardiovascular disease in transplant recipients: current and future treatment strategies. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008 , 3 Suppl 2, S29-37	6.9	48
1171	The Renin-Angiotensin System and the Aging Process. 2008 , 209-230		
1170	Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. 2008 , 24, 2389-401		43
1169	Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis. 2008 , 336, 330-5		26
1168	Renin-angiotensin system blockade is renoprotective in immune complex-mediated glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 1168-76	12.7	30
1167	N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: the African American Study of Kidney Disease and Hypertension (AASK). 2008 , 117, 1685-92		36

1166	Prognostic significance of between-arm blood pressure differences. <i>Hypertension</i> , 2008 , 51, 657-62	8.5	79
1165	Chromogranin A polymorphisms are associated with hypertensive renal disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 600-14	12.7	51
1164	Hypertension in children with chronic kidney disease: a call to action. <i>Hypertension</i> , 2008 , 52, 610-2	8.5	2
1163	Calcium antagonists: Do they equally protect against kidney injury?. 2008 , 73, 795-6		15
1162	Valsartan Amlodipine Randomized Trial (VART): design, methods, and preliminary results. 2008 , 31, 21-8		6
1161	Association of a CYP4A11 variant and blood pressure in black men. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 1606-12	12.7	45
1160	Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. 2008 , 168, 832-9		117
1159	Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression. 2008 , 120, 33-42		14
1158	Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. 2008 , 73, 963-70		25
1157	Kidney disease in the elderly: update on recent literature. 2008 , 7, 356-361		
1156	3) Brain Disorder and Renal Function. 2008 , 97, 2137-2141		0
1155	Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH. <i>Journal of Hypertension</i> , 2008 , 26, 18-25	1.9	51
1154	Outpatient management of chronic kidney disease: proteinuria, anemia and bone disease as therapeutic targets. 2008 , 15, 278-86		1
1153	Development of heart failure in recent hypertension trials. <i>Journal of Hypertension</i> , 2008 , 26, 1477-86	1.9	80
1152	Kidney disease in the elderly: update on recent literature. 2008 , 17, 298-303		29
1151	Relationship between chronic kidney disease prevalence and end-stage renal disease risk. 2008 , 17, 286-91		28
1150	Pharmacological intervention of hypertension in proteinuric chronic kidney disease: how and what?. 2008 , 121, 840-843		
1149	Progression of Chronic Kidney Disease and Renoprotective Therapy in Children. 2008 , 695-708		

1148	Lowering blood pressure reduces renal events in type 2 diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 883-92	12.7	205
1147	Treatment of mild to moderate hypertension by gender perspective: a systematic review. 2009 , 18, 1049-62		13
1146	A role for single-pill triple therapy in hypertension. 2009 , 3, 231-40		20
1145	Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients. <i>Journal of Hypertension</i> , 2009 , 27, 1136-51	1.9	73
1144	The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease. 2009 , 121, 96-103		12
1143	Aldosterone and hypertension in African Americans. <i>American Journal of Hypertension</i> , 2009 , 22, 1234	2.3	3
1142	The effect of ethnicity on the prevalence of diabetes and associated chronic kidney disease. 2009 , 102, 261-9		63
1141	Improvement of awareness, treatment and control of hypertension among chronic kidney disease patients in China from 1999 to 2005. 2009 , 32, 444-9		12
1140	Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?. 2009 , 121, 77-88		3
1139	Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians. 2009 , 121, 51-60		10
1138	Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. 2009 , 7, 689-702		26
1137	Racial differences in blood pressure response to calcium channel blocker monotherapy: a meta-analysis. <i>American Journal of Hypertension</i> , 2009 , 22, 911-7	2.3	12
1136	Prevalence of ambulatory hypotension in elderly patients with CKD stages 3 and 4. 2009 , 24, 3751-5		20
1135	G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. <i>American Journal of Hypertension</i> , 2009 , 22, 332-8	2.3	54
1134	Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis. 2009 , 24, 3677-86		10
1133	Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009 , 4, 1805-10	6.9	49
1132	Physician and pharmacist collaboration to improve blood pressure control. 2009 , 169, 1996-2002		208
1131	Strict blood-pressure control and progression of renal failure in children. 2009 , 361, 1639-50		632

1130	Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009 , 4, 1302-11	6.9	378
1129	Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. <i>Hypertension</i> , 2009 , 53, 20-7	8.5	218
1128	Antihypertensive prescriptions for newly treated patients before and after the main antihypertensive and lipid-lowering treatment to prevent heart attack trial results and seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure guidelines. <i>Hypertension</i> , 2009 , 53, 617-23	8.5	46
1127	GFR, proteinuria and circadian blood pressure. 2009 , 24, 2400-6		56
1126	Lower blood pressure goals for cardiovascular and renal risk reduction: are they defensible?. <i>Journal of Clinical Hypertension</i> , 2009 , 11, 345-7	2.3	9
1125	Underutilization of angiotensin-converting enzyme inhibitors in high-risk blacks: a case of missed opportunities. <i>Journal of Clinical Hypertension</i> , 2009 , 11, 648-50	2.3	1
1124	Commentary: counterpoint. Simple-minded antihypertensive treatment: of assumptions, potpourri, and sausages. <i>Journal of Clinical Hypertension</i> , 2009 , 11, 702-6	2.3	1
1123	Current status and future perspectives for CKD testing. 2009 , 53, S17-26		40
1122	Evidence-based practice guideline for the treatment of CKD. 2009 , 13, 537-66		95
1121	Complete remission of nephrotic syndrome in an infant with focal segmental glomerulosclerosis: is it renin-angiotensin blockade?. 2009 , 24, 1065-70		5
1120	Direct renin inhibitors: ONTARGET for success?. 2009 , 41, 341-55		1
1119	Cardiovascular disease disparities: Racial/ethnic factors and potential solutions. 2009 , 3, 187-193		10
1118	The current state of RAAS blockade in the treatment of hypertension and proteinuria. 2009 , 11, 436-42		13
1117	Hypertension in patients with chronic kidney disease. <i>Current Hypertension Reports</i> , 2009 , 11, 329-36	4.7	9
1116	Should albuminuria be a focus of antihypertensive therapy goals?. <i>Current Hypertension Reports</i> , 2009 , 11, 354-62	4.7	1
1115	Blood pressure level and kidney disease progression: do we really need to go to 130/80 mm Hg?. <i>Current Hypertension Reports</i> , 2009 , 11, 363-7	4.7	1
1114	Effect of blood pressure lowering on markers of kidney disease progression. <i>Current Hypertension Reports</i> , 2009 , 11, 368-74	4.7	4
1113	Dual renin-angiotensin system blockade in the ONTARGET study: clinically relevant risk for the kidney?. <i>Current Hypertension Reports</i> , 2009 , 11, 375-81	4.7	1

1112	Characteristics of uninsured Americans with chronic kidney disease. 2009 , 24, 917-22		37
1111	Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. 2009 , 26, 313-24		11
1110	Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidney disease. 2009 , 24, 301-7		12
1109	High prevalence of undiagnosed chronic kidney disease among at-risk population in Kinshasa, the Democratic Republic of Congo. 2009 , 10, 18		55
1108	Inhibiting the renin-angiotensin system: why and in which patients. 2009 , 21, 66-75		2
1107	Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. <i>Hypertension</i> , 2009 , 54, 32-9	8.5	138
1106	Cardiovascular risk factors in patients with chronic kidney disease. 2009 , 6, 580-9		54
1105	Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: Challenge-DM study. <i>Diabetes Research and Clinical Practice</i> , 2009 , 83, 241-8	7.4	9
1104	Endothelial dysfunction in African-Americans. 2009 , 132, 157-72		19
1103	Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease. 2009 , 157, S7-S16		27
1102	Contemporary management of atherosclerotic renovascular disease. 2009 , 50, 1197-210		16
1101	Efectos renales de los antagonistas del calcio. 2009 , 26, 116-120		
1100	Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination. 2009 , 25, 421-30		13
1099	Beta-adrenergic antagonists in hypertension: a review of the evidence. 2009 , 43, 2031-43		13
1098	Treatment blood pressure targets for hypertension. 2009 , CD004349		97
1097	Factors other than glomerular filtration rate affect serum cystatin C levels. 2009 , 75, 652-60		444
1096	Clinical practice. Renal-artery stenosis. 2009 , 361, 1972-8		112
1095	Metabolic effects of manidipine. 2009 , 9, 163-76		11

1094 [Treating high blood pressure in kidney patients: evidence and implications]. **2009**, 132 Suppl 1, 20-6

1093 Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. **2009**, 374, 525-33 302

1092 Longitudinal measurements of renal function. **2009**, 29, 650-7 21

1091 The kidney, hypertension, and remaining challenges. *Medical Clinics of North America*, **2009**, 93, 697-715, Table of Contents 7 36

1090 Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?. **2009**, 18, 386-91 15

1089 Benefits of dietary sodium restriction in the management of chronic kidney disease. **2009**, 18, 531-8 85

1088 Main results and clinical interpretations from the TRANSCEND study. *Journal of Hypertension*, **2009**, 27, S22-5 1.9 3

1087 Effects of angiotensin II receptor blockers on diabetic nephropathy. *Journal of Hypertension*, **2009**, 27, S15-21 1.9 23

1086 Slowing the progression of chronic kidney disease. **2009**, 70, 634-8 1

1085 Pharmacotherapeutic blood pressure management in a chronic kidney disease patient. **2009**, 20, 205-13; quiz 214-5

1084 Can we slow the progression of chronic kidney disease?. **2010**, 22, 170-5 10

1083 Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. *Journal of Hypertension*, **2010**, 28, 1356-65 1.9 59

1082 Strict Blood-Pressure Control and Progression of Renal Failure in Children. **2010**, 2010, 69-71

1081 Treatment blood pressure targets for hypertension. **2010**, 2010, 37-39

1080 Blood pressure targets: are clinical guidelines wrong?. **2010**, 25, 350-4 10

1079 Genetic bases of urinary albumin excretion and related traits in hypertension. *Journal of Hypertension*, **2010**, 28, 213-25 1.9 6

1078 Systematic approach for the management of chronic kidney disease: moving beyond chronic kidney disease classification. **2010**, 19, 208-13 3

1077 Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease. **2010**, 19, 140-52 23

1076	Essential hypertension and risk of nephropathy: a reappraisal. 2010 , 19, 235-41	20
1075	Renin-angiotensin system blockade in older adults with chronic kidney disease: a review of the literature. 2010 , 19, 413-9	8
1074	Aldosterone blockade in chronic kidney disease: can it improve outcome?. 2010 , 19, 444-9	24
1073	Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients. 2010 , 6, 821-7	11
1072	Journal Club. 2010 , 78, 6-7	
1071	Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease. 2010 , 25, 203-8	7
1070	The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. 2010 , 10, 37-42	28
1069	Does blockade of the Renin-Angiotensin-aldosterone system slow progression of all forms of kidney disease?. <i>Current Hypertension Reports</i> , 2010 , 12, 369-77	4-7 19
1068	The effect of fat intake and antihypertensive drug therapy on serum lipid profile: a cross-sectional survey of serum lipids in male and female hypertensives. 2010 , 343, 37-47	5
1067	Imprecision of urinary iothalamate clearance as a gold-standard measure of GFR decreases the diagnostic accuracy of kidney function estimating equations. 2010 , 56, 39-49	87
1066	Blood pressure control and progression of CKD in children. 2010 , 55, 988-91	2
1065	Blood pressure target in individuals without diabetes: what is the evidence?. 2010 , 56, 434-8	3
1064	Relationship between body mass index and proteinuria in hypertensive nephrosclerosis: results from the African American Study of Kidney Disease and Hypertension (AASK) cohort. 2010 , 56, 896-906	37
1063	Systolic blood pressure and mortality among older community-dwelling adults with CKD. 2010 , 56, 1062-71	27
1062	Deterioration of blood pressure control after discontinuation of a physician-pharmacist collaborative intervention. 2010 , 30, 228-35	41
1061	Effect of self-efficacy and social support on adherence to antihypertensive drugs. 2010 , 30, 432-41	26
1060	Are there effects of renin-angiotensin system antagonists beyond blood pressure control?. 2010 , 105, 21A-9A	34
1059	Not yet time for a paradigm shift away from angiotensin inhibitors in chronic kidney disease, but due diligence required. 2010 , 64, 1331-3	1

1058 Hypertensive Kidney Disease. **2010**, 57-67

1057 Aliskiren and valsartan combination therapy for the management of hypertension. **2010**, 6, 711-22 12

1056 Positive change in the utilization of antihypertensive and lipid-lowering drugs among adult CHD patients in Finland: results from a large national database between 2000 and 2006. **2010**, 17, 477-85 3

1055 Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. *Hypertension*, **2010**, 56, 780-800 8.5 327

1054 Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 2131-42 12.7 33

1053 Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosis. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 1361-9 12.7 39

1052 Risk factors have special relevance for living kidney donors. **2010**, 103, 627-8 1

1051 Comparative effectiveness research: evaluating pharmacist interventions and strategies to improve medication adherence. *American Journal of Hypertension*, **2010**, 23, 949-55 2.3 33

1050 Primary Hypertension. **2010**, 411-420

1049 New recommendations for treating hypertension in black patients: evidence and/or consensus?. *Hypertension*, **2010**, 56, 801-3 8.5 13

1048 Principales componentes del sistema renina-angiotensina-aldosterona: historia, modulaci3n farmacol3gica e impacto cl3nico. **2010**, 21, 516-529 1

1047 Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease. **2010**, 19, 1027-37 11

1046 Terapia antihipertensiva en enfermedad renal cr3nica. **2010**, 21, 541-552

1045 Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. *Hypertension*, **2010**, 56, 824-30 8.5 141

1044 Blood pressure control in chronic kidney disease: is less really more?. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 1086-92 12.7 69

1043 Lower BP is Better in Children With Chronic Kidney Disease. **2010**, 23, 20-20

1042 Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. **2010**, 298, F683-91 59

1041 Achieving blood pressure goal: initial therapy with valsartan/hydrochlorothiazide combination compared with monotherapy. **2010**, 24, 823-30 6

1040	Acute kidney injury following coronary angiography is associated with a long-term decline in kidney function. 2010 , 78, 803-9	157
1039	Population based screening for chronic kidney disease: cost effectiveness study. 2010 , 341, c5869	98
1038	CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. 2010 , 31, 95-103	39
1037	Progression of chronic kidney disease: Adrenergic genetic influence on glomerular filtration rate decline in hypertensive nephrosclerosis. 2010 , 32, 23-30	12
1036	CRP polymorphisms and progression of chronic kidney disease in African Americans. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010 , 5, 24-33	6.9 17
1035	Common charge-shift mutation Glu65Lys in K ⁺ channel β subunit KCNMB1: pleiotropic consequences for glomerular filtration rate and progressive renal disease. 2010 , 32, 414-24	8
1034	Hypertension control in African-American patients with chronic kidney disease. 2010 , 363, 974-6	7
1033	Non-immune interventions to protect kidney allografts in the long term. 2010 , S71-5	14
1032	Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine. 2010 , 33, 1211-20	32
1031	National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. 2010 , 78, 726-36	36
1030	Pharmacist-physician comanagement of hypertension and reduction in 24-hour ambulatory blood pressures. 2010 , 170, 1634-9	66
1029	Effectiveness of blood pressure lowering: evidence-based comparisons between men and women. 2010 , 8, 199-209	14
1028	Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model. 2010 , 78, 1136-53	109
1027	Hypertensive nephropathy: prevention and treatment recommendations. 2010 , 11, 2675-86	42
1026	Medication issues in older individuals with CKD. 2010 , 17, 320-8	11
1025	Epidemiology of hypertension in the elderly with chronic kidney disease. 2010 , 17, 329-40	9
1024	Hypertension in special populations: chronic kidney disease, organ transplant recipients, pregnancy, autonomic dysfunction, racial and ethnic populations. 2010 , 28, 623-38	4
1023	The Pediatric Patient with Chronic Kidney Disease. 2010 , 231-250	

1022	Intensive blood-pressure control in hypertensive chronic kidney disease. 2010 , 363, 918-29		511
1021	Calcium channel blockers versus other classes of drugs for hypertension. 2010 , CD003654		36
1020	Clinical benefits from combination therapy in the treatment of hypertension. 2010 , 27, 108-116		
1019	Effect of cilnidipine on normal to marginally elevated urine albumin-creatinine ratio in asymptomatic non-diabetic hypertensive patients: an exponential decay curve analysis. 2010 , 30, 699-706		1
1018	Which antihypertensive drugs are the most nephroprotective and why?. 2010 , 11, 2651-63		15
1017	Outpatient management of chronic kidney disease: proteinuria, anemia and bone disease as therapeutic targets. 2010 , 56, 215-32		1
1016	Treating high blood pressure: is reaching the target more important than the means? No, the means are important. <i>European Journal of Internal Medicine</i> , 2010 , 21, 478-83	3.9	
1015	The role of vasodilating beta-blockers in patients with complicated hypertension: focus on nebivolol. <i>American Journal of Medicine</i> , 2010 , 123, S16-20	2.4	9
1014	Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. <i>American Journal of Medicine</i> , 2010 , 123, 1016-30	2.4	77
1013	The importance of renin-angiotensin blockade in patients with cardio-renal disease. 2010 , 36 Suppl 1, 97-105		2
1012	Early recognition and prevention of chronic kidney disease. 2010 , 375, 1296-309		368
1011	Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. 2010 , 375, 1173-81		374
1010	Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. 2010 , 376, 2096-103		226
1009	2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension. 2010 , 109, 740-73		72
1008	Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials. 2010 , 15, 195-204		18
1007	Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. 2010 , 77, 617-23		199
1006	24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. 2011 , 25, 615-22		27
1005	Hypertension and CKD. 2011 , 18, 355-61		21

1004	Complications of progression of CKD. 2011 , 18, 400-5	22
1003	Implications of proteinuria: CKD progression and cardiovascular outcomes. 2011 , 18, 258-66	29
1002	Treatment of carvedilol for refractory hypertension in patients with renal diseases: A multicentre, prospective clinical trial. 2011 , 1, 203-209	1
1001	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. 2011 , 5, 259-352	325
1000	Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. 2011 , 58, 1152-61	111
999	The design of a prospective, randomized, open-labeled study to compare the efficacy of lercanidipine with amlodipine on renal function in hypertensive patients aged at least 55 years (LEADER study). 2011 , 2, 88-92	0
998	Epidemiology of hypertensive kidney disease. 2011 , 7, 11-21	80
997	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. 2011 , 79, 1331-40	468
996	Pragmatic vs. explanatory: an adaptation of the PRECIS tool helps to judge the applicability of systematic reviews for daily practice. 2011 , 64, 1095-101	48
995	[Nephroprotection, fact or fiction?]. 2011 , 40, 1037-42	1
994	Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. 2011 , 12, 65-82	264
993	Expert consensus on management of diabetic patients with impairment of renal function. 2011 , 37 Suppl 2, S1-25	15
992	Optimal renin-angiotensin-aldosterone system control: direct renin inhibitors beyond blood pressure reductions. 2011 , 1, 108-111	
991	Initial combination therapy with amlodipine/valsartan compared with monotherapy in the treatment of hypertension. 2011 , 5, 417-24	6
990	Hypertension in diverse populations: a New York State Medicaid clinical guidance document. 2011 , 5, 208-29	15
989	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. 2011 , 5, 259-352	100
988	Nefropatía hipertensiva. 2011 , 10, 5474-5483	
987	Achieving blood pressure goals: a study in uncontrolled hypertensive patients treated with a fixed-dose combination of ramipril/hydrochlorothiazide: the ASTRAL study. 2011 , 22, 79-84	5

- 986 Current Controversies over the Management of Elderly Hypertension with Impaired Renal Function. **2011**, 17, 148
- 985 Short- and long-term physiologic and pharmacologic control of blood pressure in pediatric patients. **2011**, 4, 35-44 3
- 984 A critical appraisal of the clinical effectiveness of a fixed combination of valsartan, amlodipine, and hydrochlorothiazide in achieving blood pressure goals. **2011**, 4, 1-5 10
- 983 Hypertension in chronic kidney disease: navigating the evidence. **2011**, 2011, 132405 78
- 982 Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials. *Journal of Hypertension*, **2011**, 29, 1270-80 1.9 58
- 981 What should be the blood pressure target for diabetic patients?. **2011**, 26, 308-13 9
- 980 The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. *Journal of Hypertension*, **2011**, 29, 4-16 1.9 158
- 979 Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population. *Journal of Hypertension*, **2011**, 29, 1553-9 1.9 39
- 978 Pathogenesis and management of hypertension after kidney transplantation. *Journal of Hypertension*, **2011**, 29, 2283-94 1.9 28
- 977 Blood pressure goal in chronic kidney disease: what is the evidence?. **2011**, 20, 229-32 8
- 976 Early pancreas graft failure is associated with inferior late clinical outcomes after simultaneous kidney-pancreas transplantation. **2011**, 92, 796-801 26
- 975 Potential benefits of aliskiren beyond blood pressure reduction. **2011**, 19, 90-4 3
- 974 Association of plasma renin activity and aldosterone-renin ratio with prevalence of chronic kidney disease: the Kaiser Permanente Southern California cohort. *Journal of Hypertension*, **2011**, 29, 2226-35 1.9 19
- 973 Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. **2011**, 2011, 73-76
- 972 Can an ACE inhibitor reduce the risk of developing progressive renal disease?. **2011**, 24, 51-3
- 971 Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease. **2011**, 2011, 41-42
- 970 Renal function and cardiovascular events during antihypertensive treatment in elderly patients. **2011**, 7, 59-63
- 969 Efficacy and safety of manidipine in patients with hypertension aged 70 years or older. **2011**, 7, 521-528 1

968	Protecting the kidneys in lupus nephritis. 2011 , 6, 529-546		10
967	The challenge of managing hypertension in chronic renal disease. 2011 , 3, 58-62		
966	CON: blood pressure treatment goal for patients with diabetes should be . <i>Journal of Clinical Hypertension</i> , 2011 , 13, 263-5	2.3	4
965	Blood pressure targets in diabetes: is this the time for change?--PRO (Rebuttal). <i>Journal of Clinical Hypertension</i> , 2011 , 13, 266-7	2.3	
964	Sustained blood pressure control following discontinuation of a pharmacist intervention. <i>Journal of Clinical Hypertension</i> , 2011 , 13, 431-7	2.3	28
963	The Baltimore Partnership to Educate and Achieve Control of Hypertension (The BPTEACH Trial): a randomized trial of the effect of education on improving blood pressure control in a largely African American population. <i>Journal of Clinical Hypertension</i> , 2011 , 13, 563-70	2.3	21
962	Angiotensin-converting enzyme inhibitors. <i>Journal of Clinical Hypertension</i> , 2011 , 13, 667-75	2.3	70
961	Management of chronic kidney disease. 2011 , 39, 407-413		4
960	[Blood pressure goals on the test bench]. 2011 , 123, 571-84		0
959	Clinical outcomes in patients with chronic kidney disease: a 5-year retrospective cohort study at a University Hospital in Japan. 2011 , 15, 831-40		8
958	ACE activity is modulated by the enzyme β -galactosidase A. 2011 , 89, 65-74		14
957	Kinder mit chronischer Niereninsuffizienz. <i>Der Nephrologe</i> , 2011 , 6, 169-176	0.1	
956	Progrediente Niereninsuffizienz mit großer Proteinurie. <i>Der Nephrologe</i> , 2011 , 6, 521-523	0.1	
955	Is there a role for measuring central aortic pressure?. 2011 , 13, 502-6		3
954	What is the ideal blood pressure goal for patients with stage III or higher chronic kidney disease?. 2011 , 13, 492-501		10
953	Should β -blockers no longer be considered first-line therapy for the treatment of essential hypertension without comorbidities?. 2011 , 13, 507-16		20
952	Discord from ACCORD?. <i>Current Hypertension Reports</i> , 2011 , 13, 1-4	4.7	1
951	How much blood pressure control is beneficial in patients with chronic kidney disease?. <i>Current Hypertension Reports</i> , 2011 , 13, 93-5	4.7	

950	Is nocturnal blood pressure reduction the secret to reducing the rate of progression of hypertensive chronic kidney disease?. <i>Current Hypertension Reports</i> , 2011 , 13, 378-85	4.7	26
949	Blood pressure targets for patients with diabetes or kidney disease. <i>Current Hypertension Reports</i> , 2011 , 13, 452-5	4.7	14
948	Association of blood pressure with decline in renal function and time until the start of renal replacement therapy in pre-dialysis patients: a cohort study. 2011 , 12, 38		11
947	The relationship of ethnicity to the prevalence and management of hypertension and associated chronic kidney disease. 2011 , 12, 41		27
946	The chronic kidney disease model: a general purpose model of disease progression and treatment. 2011 , 11, 41		18
945	Antihypertensive medication use and change in kidney function in elderly adults: a marginal structural model analysis. 2011 , 7, Article 34		2
944	The lingering dilemma of arterial pressure in CKD: what do we know, where do we go?. 2011 , 1, 17-20		8
943	Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans. 2011 , 79, 356-62		129
942	Renoprotective effects of benazepril: current perspective. 2011 , 9, 663-73		1
941	Patterns and prognostic value of total and differential leukocyte count in chronic kidney disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 1393-9	6.9	24
940	Angiotensin II type 1A receptors in vascular smooth muscle cells do not influence aortic remodeling in hypertension. <i>Hypertension</i> , 2011 , 57, 577-85	8.5	48
939	Blood Pressure Goals in CKD: Where Are We Going, and How Do We Get There?. 2011 , 4, 11-13		
938	Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 1545-52	27.4	291
937	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. 2011 , 123, 2434-506		255
936	The spectrum of albuminuria as a predictor of cardiorenal outcomes. 2011 , 8, 569-579		
935	Pediatric GFR estimating equations applied to adolescents in the general population. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 1427-35	6.9	79
934	Relationship between blood pressure and incident chronic kidney disease in hypertensive patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 2605-11	6.9	42
933	Metabolic syndrome and renal injury. 2011 , 2011, 567389		15

932	Relapse or worsening of nephrotic syndrome in idiopathic membranous nephropathy can occur even though the glomerular immune deposits have been eradicated. 2011 , 119, c145-53		7
931	Renal Association Clinical Practice Guideline on detection, monitoring and management of patients with CKD. 2011 , 118 Suppl 1, c71-c100		18
930	Control of blood pressure in chronic kidney disease: how low to go?. 2011 , 119, c324-31; discussion c331-2		6
929	(1)-adrenergic receptor polymorphisms and response to β -blockade in the African-American study of kidney disease and hypertension (AASK). <i>American Journal of Hypertension</i> , 2011 , 24, 694-700	2.3	5
928	Hypertensive Cardiovascular and Renal Disease and Target Organ Damage: Lessons from Animal Models. 2011 , 1, 139-146		17
927	Hypertension in Cardiovascular and Kidney Disease. 2011 , 1, 183-192		33
926	Trefoil factor 3 predicts incident chronic kidney disease: a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) study. 2011 , 34, 291-7		29
925	Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset. 2011 , 26, 848-57		20
924	Chronic kidney disease as a coronary disease equivalent--a comparison with diabetes over a decade. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 1385-92	6.9	34
923	Mixed messages on blood pressure goals. <i>Hypertension</i> , 2011 , 57, 1039-40	8.5	18
922	FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2011 , 22, 1913-22	12.7	361
921	Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial. <i>Hypertension</i> , 2011 , 57, 1061-8	8.5	38
920	Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate. 2011 , 34, 1121-6		5
919	Quality of care and mortality are worse in chronic kidney disease patients living in remote areas. 2011 , 79, 210-7		72
918	L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats. 2011 , 34, 521-9		24
917	Combination inhibition of the renin-angiotensin system: is more better?. 2011 , 80, 245-55		13
916	Managing kidney disease with blood-pressure control. 2011 , 7, 434-44		31
915	Determinants and prognostic significance of electrocardiographic left ventricular hypertrophy criteria in chronic kidney disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 528-36	6.9	17

914	Renal injury in angiotensin II+L-NAME-induced hypertensive rats is independent of elevated blood pressure. 2011 , 300, F1008-16		19
913	Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. 2012 , 9, e1001293		77
912	Effect of an Oral Adsorbent, AST-120, on Dialysis Initiation and Survival in Patients with Chronic Kidney Disease. 2012 , 2012, 376128		26
911	Kidney disease in disadvantaged populations. 2012 , 2012, 469265		16
910	Improvement in kidney function: a real occurrence. <i>Journal of the American Society of Nephrology: JASN</i> , 2012 , 23, 575-7	12.7	1
909	Dietary management of chronic kidney disease: protein restriction and beyond. 2012 , 21, 635-40		25
908	Is the lower blood pressure target for patients with chronic kidney disease supported by evidence?. 2012 , 27, 370-3		5
907	Renin-Angiotensin-Aldosterone system and the kidney. 2012 , 76-84		
906	Switching to an L/N-type calcium channel blocker shows renoprotective effects in patients with chronic kidney disease: the Kyoto Cilnidipine Study. 2012 , 40, 1417-28		11
905	Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012 , 7, 989-1002	6.9	64
904	Beta-blockers for hypertension. 2012 , CD002003		21
903	Proteinuria should be used as a surrogate in CKD. 2012 , 8, 301-6		103
902	Prehypertension and chronic kidney disease: the ox or the plow?. 2012 , 81, 229-32		3
901	Pathophysiologic therapeutic targets in hypertension: a cardiological point of view. 2012 , 16, 179-93		9
900	Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. 2012 , 26, 502-6		37
899	Renoprotective and antioxidant effects of cilnidipine in hypertensive patients. 2012 , 35, 1058-62		14
898	Proteinuria as a risk marker for the progression of chronic kidney disease in patients on predialysis care and the role of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment. 2012 , 121, c73-82		8
897	Impact of serum uric acid on renal function and cardiovascular events in hypertensive patients treated with losartan. 2012 , 35, 867-73		28

896	Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern?. 2012 , 34, 1095-9		35
895	Hypertension in the elderly. 2012 , 4, 135-47		112
894	Factors associated with chronic kidney disease progression in Australian nephrology practices. 2012 , 121, c36-41		5
893	Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 1941-51	27.4	658
892	Age and association of kidney measures with mortality and end-stage renal disease. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 2349-60	27.4	371
891	Blood pressure indexes and end-stage renal disease risk in adults with chronic kidney disease. <i>American Journal of Hypertension</i> , 2012 , 25, 789-96	2.3	34
890	Validating a case definition for chronic kidney disease using administrative data. 2012 , 27, 1826-31		62
889	Proteinuria among patients with chronic kidney disease: a performance measure for improving patient outcomes. 2012 , 38, 277-82		5
888	Methylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC). 2012 , 27, 197-205		17
887	Risk factors for end-stage kidney disease after pediatric liver transplantation. 2012 , 12, 3398-405		23
886	Educational paper: Progression in chronic kidney disease and prevention strategies. 2012 , 171, 1579-88		22
885	The effects of blood pressure control levels on the renoprotection of type 2 diabetic patients without overt proteinuria. 2012 , 6, 124-31		9
884	Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with stage 2 hypertension. 2012 , 6, 219-27		6
883	Quality of life and psychosocial factors in African Americans with hypertensive chronic kidney disease. 2012 , 159, 4-11		26
882	Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART. 2012 , 26, 656-63		4
881	Effects of the combinations of amlodipine/valsartan versus losartan/hydrochlorothiazide on left ventricular hypertrophy as determined with magnetic resonance imaging in patients with hypertension. 2012 , 1, 1-10		3
880	Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. 2012 , 126, 2105-14		379
879	The controversies of diagnosing and treating hypertension among hemodialysis patients. 2012 , 25, 370-6		14

878	Renal endpoints in renal and cardiovascular randomized clinical trials: time for a consensus?. 2012 , 26, 771-82		11
877	Nocturnal medications dosing: does it really make a difference in blood pressure control among patients with chronic kidney disease?. <i>Current Hypertension Reports</i> , 2012 , 14, 449-54	4-7	2
876	Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. 2012 , 110, 383-91		113
875	The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. 2012 , 28, 270-87		133
874	Reduced incidence of end stage renal disease among the elderly in Denmark: an observational study. 2012 , 13, 131		12
873	Hypertension resistant to antihypertensive agents commonly occurs with the progression of diabetic nephropathy in Japanese patients with type 2 diabetes mellitus: a prospective observational study. 2012 , 13, 48		10
872	Beta-blockers for hypertension. 2012 , 11, CD002003		69
871	Mechanisms and treatment of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2012 , 23, 1917-28.7		176
870	Hypertension and chronic kidney disease progression: why the suboptimal outcomes?. <i>American Journal of Medicine</i> , 2012 , 125, 1057-62	2-4	24
869	Etiology and management of hypertension in chronic kidney disease. 2012 , 1, 259-267		2
868	Metalloproteinases: key and common mediators of multiple GPCRs and candidate therapeutic targets in models of hypertensive cardiac disease. 2012 , 9, e103-e108		2
867	Hypertension in African Americans. 2012 , 25-34		
866	Hypertension in Chronic Kidney Disease. 2012 , 35-50		
865	Novel insights into the relationship between glomerular pathology and progressive kidney disease. 2012 , 19, 93-100		25
864	Sleep disturbances as nontraditional risk factors for development and progression of CKD: review of the evidence. 2012 , 60, 823-33		96
863	What is the ideal blood pressure goal for patients with diabetes mellitus and nephropathy?. 2012 , 14, 651-9		6
862	Heart rate and blood pressure: any possible implications for management of hypertension?. <i>Current Hypertension Reports</i> , 2012 , 14, 478-84	4-7	44
861	Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study. 2012 , 12, 233-43		18

860	Fixed-dose combination therapy in hypertension: cons. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2012 , 19, 51-4	2.9	13
859	Renal function trajectory is more important than chronic kidney disease stage for managing patients with chronic kidney disease. 2012 , 36, 1-10		57
858	Schwartz formula: is one k-coefficient adequate for all children?. 2012 , 7, e53439		59
857	Primary hypertension. 2012 , 437-443		1
856	Hypertensive chronic kidney disease in African Americans: strategies for improving care. 2012 , 79, 726-34		19
855	Cardio classics revisited: focus on the role of amlodipine. 2012 , 5, 1-7		2
854	Nonparametric multistate representations of survival and longitudinal data with measurement error. 2012 , 31, 2303-17		4
853	Glomerular hyperfiltration and renal disease progression in type 2 diabetes. 2012 , 35, 2061-8		212
852	Association of renal function with the ambulatory arterial stiffness index and pulse pressure in hypertensive patients. 2012 , 35, 201-6		13
851	Kidney function can improve in patients with hypertensive CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2012 , 23, 706-13	12.7	35
850	Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. 2012 , 27, 458-68		35
849	Approach to cardiovascular disease prevention in patients with chronic kidney disease. 2012 , 14, 391-413		7
848	J Curve in Hypertension. 2012 , 6, 281-290		6
847	Longitudinal progression trajectory of GFR among patients with CKD. 2012 , 59, 504-12		210
846	Optimizing care for patients with CKD. 2012 , 60, 133-8		20
845	Target organ damage in African American hypertension: role of APOL1. <i>Current Hypertension Reports</i> , 2012 , 14, 21-8	4.7	40
844	Arterielle Hypertonie als Progressionsfaktor der chronischen Niereninsuffizienz. <i>Der Nephrologe</i> , 2012 , 7, 18-27	0.1	
843	Efficient synthesis of hydroxyl isoindolones by a Pd-mediated C-H activation/annulation reaction. 2013 , 19, 11184-8		62

842	Blood pressure, proteinuria, and phosphate as risk factors for progressive kidney disease: a hypothesis. 2013 , 62, 984-92	29
841	Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. 2013 , 159, 233-42	146
840	Pharmacologic management of chronic reno-cardiac syndrome. 2013 , 10, 54-62	11
839	A consideration of genetic mechanisms behind the development of hypertension in blacks. <i>Current Hypertension Reports</i> , 2013 , 15, 108-13	4-7 30
838	Effectiveness and safety of aliskiren and aliskiren hydrochlorothiazide (HCT) in a multiethnic, real-world setting. 2013 , 30, 176-89	2
837	Improvement and influencing factors of blood pressure control by nephrologist referral in chronic kidney disease patients in China: a cohort study. 2013 , 45, 1345-53	4
836	A review of the efficacy and tolerability of combination amlodipine/valsartan in non-white patients with hypertension. 2013 , 13, 301-13	11
835	Cystatin C versus creatinine in determining risk based on kidney function. 2013 , 369, 932-43	541
834	Efficacy and safety of two ramipril and hydrochlorothiazide fixed-dose combination formulations in adults with stage 1 or stage 2 arterial hypertension evaluated by using ABPM. 2013 , 35, 702-10	4
833	Hypertension management: rationale for triple therapy based on mechanisms of action. 2013 , 31, 251-8	28
832	Hypertension in chronic kidney disease. 2013 , 2, 15-22	1
831	Calcium Channel Blockers in Hypertension. 2013 , 204-218	2
830	The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups. 2013 , 30, 1067-85	8
829	Difference in blood pressure response to ACE-Inhibitor monotherapy between black and white adults with arterial hypertension: a meta-analysis of 13 clinical trials. 2013 , 14, 201	22
828	Pharmacologic treatment of hypertension in patients with chronic kidney disease. 2013 , 13, 177-88	6
827	Chronic kidney disease in the elderly. 2013 , 29, 611-24	14
826	Renal protection with calcium antagonists: the role of lercanidipine. 2013 , 29, 1727-35	10
825	Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension. 2013 , 29, 901-10	11

824	Wat te doen bij chronische nierschade?. 2013 , 56, 652-657		
823	Chronische nierschade: een zorg voor de eerste lijn. 2013 , 8, 66-72		3
822	Pharmacologic Management of Hypertension. 2013 , 474-489		3
821	Role of dihydropyridinic calcium channel blockers in the management of hypertension. 2013 , 11, 91-105		13
820	Chronic Kidney Disease: Pathophysiology and the Influence of Dietary Protein. 2013 , 3021-3072		
819	Kidney Disease in Hypertension. 2013 , 270-279		
818	APOL1 and nephropathy progression in populations of African ancestry. 2013 , 33, 425-32		20
817	Hypertension. 2013 , 40, 179-94		15
816	Advanced oxidation protein products activate intrarenal renin-angiotensin system via a CD36-mediated, redox-dependent pathway. 2013 , 18, 19-35		57
815	Risk factors for ESRD in individuals with preserved estimated GFR with and without albuminuria: results from the Kidney Early Evaluation Program (KEEP). 2013 , 61, S4-11		29
814	Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. 2013 , 61, 211-8		55
813	Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. 2013 , 76, 516-23		70
812	Ambulatory blood pressure monitoring trumps estimated glomerular filtration rate in predicting cardiovascular risk in low-risk populations. <i>Hypertension</i> , 2013 , 61, 14-5	8.5	1
811	References. 2013 , 3, 136-150		66
810	Chronic Kidney Disease: Definitions and General Approach. 2013 , 251-262		
809	Goals of Therapy: Slowing Progression and Dyslipidemias. 2013 , 287-297		
808	Cardiovascular Complications in Patients with Renal Disease. 2013 , 687-700		
807	2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. 2013 , 22, 193-278		286

806	Immune and inflammatory role in renal disease. 2013 , 3, 957-76		185
805	2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 , 34, 2159-219		3400
804	[J curve: when lowering blood pressure becomes a hazard?]. 2013 , 54, 376-82		1
803	Hypertension in elderly. 2013 , 2, 96-102		0
802	Differential diagnosis of glomerular disease: a systematic and inclusive approach. 2013 , 38, 253-66		27
801	The 2012-2013 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: An update. 2013 , 146, 146-50		13
800	Management of hypertension with fixed-dose triple-combination treatments. 2013 , 7, 246-59		12
799	Military nephrology: magnitude of rates of deterioration in renal function. 2013 , 159, 98-101		1
798	Effect of CD40 and sCD40L on renal function and survival in patients with renal artery stenosis. <i>Hypertension</i> , 2013 , 61, 894-900	8.5	15
797	Effect of intensive blood pressure control on cardiovascular remodeling in hypertensive patients with nephrosclerosis. 2013 , 2013, 120167		2
796	Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. 2013 , 347, f5680		157
795	Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients. 2013 , 20, 2-12		6
794	Current issues in the management and monitoring of hypertension in chronic kidney disease. 2013 , 22, 599-606		8
793	2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>Journal of Hypertension</i> , 2013 , 31, 1281-357	1.9	3363
792	What should be the blood pressure target for patients with chronic kidney disease?. 2013 , 28, 439-45		6
791	Mineral metabolites and CKD progression in African Americans. <i>Journal of the American Society of Nephrology: JASN</i> , 2013 , 24, 125-35	12.7	68
790	Differential modulation of uncoupling protein 2 in kidneys of stroke-prone spontaneously hypertensive rats under high-salt/low-potassium diet. <i>Hypertension</i> , 2013 , 61, 534-41	8.5	48
789	Hypertension in black patients: an update. 2013 , 125, 127-35		4

788	Is lipid management effective for all stages of CKD?. 2013 , 35, 26-30		8
787	Blood pressure targets in chronic kidney disease: does proteinuria dictate how low we go?. 2013 , 185, 941-2		5
786	Loss of GSTM1, a NRF2 target, is associated with accelerated progression of hypertensive kidney disease in the African American Study of Kidney Disease (AASK). 2013 , 304, F348-55		41
785	Relationship of left ventricular hypertrophy and diastolic function with cardiovascular and renal outcomes in African Americans with hypertensive chronic kidney disease. <i>Hypertension</i> , 2013 , 62, 518-25 ^{8.5}		31
784	Resistant hypertension in nondialysis chronic kidney disease. 2013 , 2013, 929183		23
783	Improving approaches to hypertension treatment in African Americans: lessons learned from the Jackson Heart Study. <i>Journal of Clinical Hypertension</i> , 2013 , 15, 362-4	2.3	3
782	Similar blood pressure values across racial and economic groups: baseline data from a group randomized clinical trial. <i>Journal of Clinical Hypertension</i> , 2013 , 15, 404-12	2.3	11
781	Ramipril. 2013 , 30, 39-41a		0
780	Association of BP variability with mortality among African Americans with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013 , 8, 731-8	6.9	40
779	Renoprotective strategies in lupus nephritis: beyond immunosuppression. 2013 , 22, 1267-73		19
778	Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control. 2013 , 22, 623-31		29
777	Blood pressure targets for patients with chronic kidney disease. 2013 , 22, 395-396		1
776	The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review. 2013 , 36, 91-101		26
775	APOL1 risk variants, race, and progression of chronic kidney disease. 2013 , 369, 2183-96		492
774	Slowing chronic kidney disease progression: should we be looking beyond mean blood pressure?. 2013 , 36, 112-4		
773	Blood pressure and chronic kidney disease progression in a multi-racial cohort: the Multi-Ethnic Study of Atherosclerosis. 2013 , 27, 421-6		11
772	Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. 2013 , 83, 114-20		166
771	Serum potassium predicts time to blood pressure response among African Americans with hypertensive nephrosclerosis. 2013 , 27, 393-6		1

770	Renin-angiotensin-aldosterone system blockade in hypertensive patients with chronic kidney disease. 2013 , 22, 397-398	
769	Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. 2013 , 185, 949-57	177
768	Dietary Protein Intake and Renal Function. 2013 , 121-140	
767	Opinions on the new blood pressure target in chronic kidney disease recommended by 2013 ESH/ESC guidelines for the management of arterial hypertension. <i>Journal of Hypertension</i> , 2013 , 31, 2320-9	
766	Effect of shared care on blood pressure in patients with chronic kidney disease: a cluster randomised controlled trial. 2013 , 63, e798-806	23
765	Heritable influence of DBH on adrenergic and renal function: twin and disease studies. 2013 , 8, e82956	9
764	Clinical and demographic characteristics of chronic kidney disease patients in a tertiary facility in Ghana. 2014 , 18, 274	15
763	African Americans, hypertension and the renin angiotensin system. 2014 , 6, 878-89	38
762	Do black patients with chronic kidney disease benefit equally from all blood pressure lowering agents?. 2014 , 348, g142	1
761	The effect of renin-angiotensin system blockade on renal protection in chronic kidney disease patients with hyperkalemia. 2014 , 15, 491-7	9
760	Besondere Bluthochdruckfälle. 2014 , 8, 419-428	
759	Update on Clinical Guidelines for Treatment of Hypertension. 2014 , 8, 1	
758	Chapter 6. Hypertension associated with organ damage. 2014 , 37, 301-314	
757	Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?. 2014 , 85, 536-46	48
756	Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate. 2014 , 86, 1031-8	206
755	Contrast-associated AKI and use of cardiovascular medications after acute coronary syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014 , 9, 1840-8	6.9 14
754	Quality of life and outcomes in African Americans with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 1849-55	12.7 25
753	Lack of diversity in orthopaedic trials conducted in the United States. 2014 , 96, e56	24

752	Critical blood pressure threshold dependence of hypertensive injury and repair in a malignant nephrosclerosis model. <i>Hypertension</i> , 2014 , 64, 801-7	8.5	16
751	Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar. 2014 , 86, 819-27		52
750	Use of renin-angiotensin system blockade in patients with renal artery stenosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014 , 9, 1149-52	6.9	3
749	Antihypertensive drug therapy in patients with African ancestry. 2014 , 15, 1061-4		1
748	A mixed-method approach to evaluate a pharmacist intervention for veterans with hypertension. <i>Journal of Clinical Hypertension</i> , 2014 , 16, 133-40	2.3	9
747	Plasma renin activity and its association with ischemic heart disease, congestive heart failure, and cerebrovascular disease in a large hypertensive cohort. <i>Journal of Clinical Hypertension</i> , 2014 , 16, 805-13 ^{2,3}		4
746	Obstructive sleep apnea syndrome and chronic kidney disease: a new cardiorenal risk factor. 2014 , 36, 211-6		23
745	Hypertension and kidney disease. 2014 , 8, 855-7; quiz 858-9		3
744	Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study. 2014 , 64, 867-79		47
743	GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials. 2014 , 64, 848-59		83
742	GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials. 2014 , 64, 860-6		78
741	Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. 2014 , 45, 1545-88		560
740	Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>Journal of Clinical Hypertension</i> , 2014 , 16, 14-26	2.3	588
739	What should be the goal blood pressure in nondiabetic chronic kidney disease?. 2014 , 23, 180-5		4
738	Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. <i>Journal of Hypertension</i> , 2014 , 32, 2285-95	1.9	169
737	Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease. 2014 , 174, 1442-9		71
736	Proteinuria in Hypertensive Nephropathy: A Review. 2014 , 04, 92-99		2
735	Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy. <i>Korean Journal of Internal Medicine</i> , 2014 , 29, 315-24	2.5	14

734	Beta-Blockers in the Management of Hypertension and/or Chronic Kidney Disease. 2014 , 2014, 919256		21
733	Recognition of CKD after the introduction of automated reporting of estimated GFR in the Veterans Health Administration. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014 , 9, 29-36	6.9	16
732	Association of kidney disease outcomes with risk factors for CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. 2014 , 63, 236-43		81
731	Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. 2014 , 64, 74-85		78
730	Lowering blood pressure to lower the risk of cardiovascular events in CKD. 2014 , 63, 900-2		1
729	Blockers in hypertension: studies and meta-analyses over the years. 2014 , 30, S16-22		45
728	Nephropathy in youth and young adults with type 2 diabetes. 2014 , 14, 456		14
727	Should African Americans with hypertension be treated differently than non-African Americans?. <i>Current Hypertension Reports</i> , 2014 , 16, 409	4-7	8
726	Hypertension in hemodialysis patients: an opinion-based update. 2014 , 27, 146-53		10
725	Changes in blood pressure classification, blood pressure goals and pharmacological treatment of essential hypertension in medical guidelines from 2003 to 2013. 2014 , 2, 1-10		2
724	Definition, identification and treatment of resistant hypertension in chronic kidney disease patients. 2014 , 29, 1327-35		16
723	Sodium intake and renal outcomes: a systematic review. <i>American Journal of Hypertension</i> , 2014 , 27, 1271-84		46
722	Chronische nierschade, implementatie richtlijnen en transmurale afstemming. 2014 , 30, 21-25		
721	Een samenwerkingsmodel voor patiënten met chronische nierschade. 2014 , 57, 232-235		
720	Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors. 2014 , 41, 765-78		18
719	Commentary on the 2014 BP guidelines from the panel appointed to the Eighth Joint National Committee (JNC 8). <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 2419-24	12.7	25
718	Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. 2014 , 64, 588-97		105
717	Prevalence and predictors of resistant hypertension in a primary care setting: a cross-sectional study. 2014 , 15, 131		12

716	Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. 2014 , 59, e96-138	209
715	Hypertension: is it time to reconsider blood pressure guidelines?. 2014 , 10, 620-1	2
714	Prescription pattern of Chinese herbal products for hypertension in Taiwan: a population-based study. 2014 , 155, 1534-40	24
713	Atenolol vs nonatenolol β blockers for the treatment of hypertension: a meta-analysis. 2014 , 30, S47-53	49
712	Prevalence and factors associated with left ventricular remodeling in renal artery stenosis. 2014 , 8, 254-61	12
711	Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. 2014 , 37, 993-8	10
710	Preventing the progression of chronic kidney disease: two case reports and review of the literature. 2014 , 46, 2167-74	3
709	Electronic problem list documentation of chronic kidney disease and quality of care. 2014 , 15, 70	22
708	Sequential RAAS blockade: is it worth the risk?. 2014 , 21, 159-65	8
707	KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. 2014 , 63, 713-35	866
706	Guidelines and Straitjackets: blood pressure targets in the era of the Eighth Joint National Committee. 2014 , 63, 895-9	2
705	Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease. 2014 , 21, 281-6	41
704	Canadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for the management of blood pressure in CKD. 2014 , 63, 869-87	22
703	Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. 2014 , 34, 333-9	103
702	Optimizing blood pressure control in patients with nondiabetic glomerular disease. 2014 , 21, 200-4	3
701	Call for the use of a common equation for glomerular filtration rate estimation in East and South-East Asia. 2014 , 47, 1214-9	
700	The J-curve in arterial hypertension: fact or fallacy?. 2014 , 129, 126-35	16
699	The Association of Losartan and Ramipril Therapy With Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: A Chinese Nation-Wide Cohort Study in Taiwan. 2015 , 94, e1999	7

698	US Hypertension Management Guidelines: A Review of the Recent Past and Recommendations for the Future. 2015 , 4,		42
697	Sustained Blood Pressure Control Following Discontinuation of a Pharmacist Intervention for Veterans. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 701-8	2.3	5
696	[Hypertension: The Points of Management of Hypertension for All Physicians--Based on the JSH 2014 Hypertension Guidelines--. Topics: V. Points of hypertension treatment for the patients complicated by kidney diseases and diabetes]. 2015 , 104, 240-6		
695	The Korean Society of Hypertension Guidelines for the Management of Hypertension in 2013: Its Essentials and Key Points. 2015 , 3, 21-8		29
694	Association of the ADRB2 (rs2053044) polymorphism and angiotensin-converting enzyme-inhibitor blood pressure response in the African American Study of Kidney Disease and Hypertension. 2015 , 25, 444-9		8
693	Uncontrolled hypertension by the 2014 evidence-based guideline: results from NHANES 2011-2012. <i>Journal of Hypertension</i> , 2015 , 33, 644-51; discussion 652	1.9	22
692	Interdisciplinary care clinics in chronic kidney disease. 2015 , 16, 161		24
691	Renal end points in clinical trials of kidney disease. 2015 , 24, 284-9		10
690	Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses. <i>Journal of Hypertension</i> , 2015 , 33, 1321-41	1.9	85
689	Renin-Angiotensin-Aldosterone System Blockers in Elderly Adults with Chronic Kidney Disease without Diabetes Mellitus or Proteinuria. 2015 , 63, 2478-2484		4
688	Protective effects of Brassica oleracea sprouts extract toward renal damage in high-salt-fed SHRSP: role of AMPK/PPAR α /UCP2 axis. <i>Journal of Hypertension</i> , 2015 , 33, 1465-79	1.9	26
687	Hypertension and chronic kidney disease: respective contribution of mean and pulse pressure and arterial stiffness. <i>Journal of Hypertension</i> , 2015 , 33, 2010-5	1.9	8
686	2014 Hypertension Guideline: Recommendation for a Change in Goal Systolic Blood Pressure. 2015 , 19, 64-8		2
685	Strategies for Controlling Blood Pressure and Reducing Cardiovascular Disease Risk in Patients with Chronic Kidney Disease. 2015 , 25, 515-20		4
684	Inhibition of RAS in diabetic nephropathy. 2015 , 8, 29-40		40
683	Hypertension in minority populations: new guidelines and emerging concepts. 2015 , 22, 145-53		21
682	Time-updated systolic blood pressure and the progression of chronic kidney disease: a cohort study. 2015 , 162, 258-65		87
681	Differences between early and late readmissions among patients: a cohort study. 2015 , 162, 741-9		102

680	Changes in Guideline Trends and Applications in Practice: JNC 2013 and the Future. 2015 , 1-10		
679	Impact of Chronic Kidney Disease and Diabetes Mellitus on Choice of Renin Angiotensin System-Inhibitors in Patients with Hypertension and Heart Failure. 2015 , 73-118		
678	Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 2289-302	12.7	34
677	Cardiovascular risk factors contribute to disparities in graft outcomes in African American renal transplant recipients: a retrospective analysis. 2015 , 24, 14-22		7
676	Blood pressure targets and absolute cardiovascular risk. <i>Hypertension</i> , 2015 , 66, 280-5	8.5	6
675	Defining, Treating, and Understanding Chronic Kidney Disease--A Complex Disorder. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 514-27	2.3	14
674	Hypertension in the African American population: A succinct look at its epidemiology, pathogenesis, and therapy. 2015 , 35, 139-145		8
673	Angiotensin II-mediated GFR decline in subtotal nephrectomy is due to acid retention associated with reduced GFR. 2015 , 30, 762-70		44
672	Instrumental variable methods to assess quality of care the marginal effects of process-of-care on blood pressure change and treatment costs. 2015 , 11, e69-83		2
671	The organ-protective effect of N-type Ca(2+) channel blockade. 2015 , 151, 1-7		5
670	A Salt-Induced Reno-Cerebral Reflex Activates Renin-Angiotensin Systems and Promotes CKD Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 1619-33	12.7	68
669	Integration of a Team Approach to Hypertension Treatment. 2015 , 199-212		1
668	Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 2055-64	12.7	158
667	First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. 2015 , 1, CD008170		22
666	Blood pressure targets in CKD. 2015 , 22, 96-101		5
665	Epidemiology of hypertension in CKD. 2015 , 22, 88-95		82
664	Stricter systolic blood pressure control is associated with higher all-cause mortality in patients with chronic kidney disease. 2015 , 20, 68		1
663	Renal denervation for resistant hypertension and beyond. 2015 , 22, 133-9		4

662	Management of hypertension in chronic kidney disease. 2015 , 11, 555-63		43
661	Self-management in chronic disease: clear benefits for blood pressure control in CKD. 2015 , 66, 12-4		3
660	Association of BP with Death, Cardiovascular Events, and Progression to Chronic Dialysis in Patients with Advanced Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 934-40	6.9	17
659	Rate of change in renal function and mortality in elderly treated hypertensive patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 1154-61	6.9	12
658	Measured glomerular filtration rate is the goal, but how to measure it?. 2015 , 30, 1231-3		
657	Implications of the Eighth Joint National Committee Guidelines for the Management of High Blood Pressure for Aging Adults: Atherosclerosis Risk in Communities Study. <i>Hypertension</i> , 2015 , 66, 474-80	8.5	10
656	BP Components in Advanced CKD and the Competing Risks of Death, ESRD, and Cardiovascular Events. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 911-3	6.9	2
655	The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. 2015 , 17, 329-39		62
654	Blood Pressure, Proteinuria, and Renal Function Decline: Associations in a Large Community-Based Population. <i>American Journal of Hypertension</i> , 2015 , 28, 1150-6	2.3	31
653	Management of chronic kidney disease. 2015 , 43, 454-461		3
652	Optimal blood pressure targets in 2014 - Does the guideline recommendation match the evidence base?. 2015 , 32, 71-82		
651	Management of hypertension in patients with chronic kidney disease. 2015 , 5, S43-S48		
650	A perspective on the 2013 US guidelines for hypertension: Where does the so called Evidence based approach fall short?. 2015 , 5, S10-S14		
649	Variability in estimated glomerular filtration rate values is a risk factor in chronic kidney disease progression among patients with diabetes. 2015 , 16, 34		17
648	New agents for hyperkalemia. 2015 , 372, 1570-1		2
647	The effectiveness of perindopril vs. lisinopril on reducing the incidence of diabetes and renal diseases: A cohort study of 20,252 patients. 2015 , 190, 384-8		2
646	2013 Korean Society of Hypertension guidelines for the management of hypertension: part III-hypertension in special situations. 2015 , 21, 3		9
645	2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension. 2015 , 21, 2		25

644	Nephrosclerosis: a term in quest of a disease. 2015 , 129, 276-82		36
643	Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease. 2015 , 87, 1055-60		49
642	Bayesian analysis of glomerular filtration rate trajectories in kidney transplant recipients: a pilot study. 2015 , 99, 533-9		5
641	Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. 2015 , 116, 1058-73		101
640	Impact of automated reporting of estimated glomerular filtration rate in the veterans health administration. 2015 , 53, 177-83		6
639	The Role of Systemic Blood Pressure in the Progression of Chronic Kidney Disease. 2015 , 9, 1		7
638	Longitudinal changes in hematocrit in hypertensive chronic kidney disease: results from the African-American Study of Kidney Disease and Hypertension (AASK). 2015 , 30, 1329-35		5
637	Association of heart rate with albuminuria in a general adult population: the 2011 Korea National Health and Nutrition Examination Survey. 2015 , 45, 428-35		2
636	Cluster-randomized trial of a physician/pharmacist collaborative model to improve blood pressure control. 2015 , 8, 235-43		71
635	Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 2128-35	6.9	24
634	Outcomes with Angiotensin-converting Enzyme Inhibitors vs Other Antihypertensive Agents in Hypertensive Blacks. <i>American Journal of Medicine</i> , 2015 , 128, 1195-203	2.4	17
633	Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitor-Based Treatment on Cardiovascular Outcomes in Hypertensive Blacks Versus Whites. 2015 , 66, 1224-1233		31
632	Hypertension and chronic kidney disease. 2015 , 61, 387-95		28
631	Online clinical pathway for managing adults with chronic kidney disease. 2015 , 148, 257-62		9
630	Comparison of risk factors for acute worsening renal function in heart failure patients with and without preserved ejection fraction. <i>European Journal of Internal Medicine</i> , 2015 , 26, 599-602	3.9	4
629	Advances in treatment of hyperkalemia in chronic kidney disease. 2015 , 16, 2205-15		19
628	What Are Optimal Blood Pressure Targets for Patients with Hypertension and Chronic Kidney Disease?. 2015 , 17, 101		7
627	Cost-Effectiveness of a Physician-Pharmacist Collaboration Intervention to Improve Blood Pressure Control. <i>Hypertension</i> , 2015 , 66, 1145-51	8.5	52

626	Utilization patterns of antihypertensive drugs among the chronic kidney disease population in the United States: a cross-sectional analysis of the national health and nutrition examination survey. 2015 , 37, 188-96		7
625	Blood pressure in chronic kidney disease: does the emperor have new clothes?. <i>Hypertension</i> , 2015 , 65, 27-8	8.5	
624	Treatment of hypertension in children with chronic kidney disease. <i>Current Hypertension Reports</i> , 2015 , 17, 503	4.7	12
623	Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management. 2015 , 65, 177-205		73
622	Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist. 2015 , 30, 375-84		67
621	Approach to the Patient with Hypertensive Nephrosclerosis. 2015 , 455-469		
620	Pathophysiology of Hypertension in Chronic Kidney Disease. 2015 , 163-169		3
619	Clinical Assessment and Management of Chronic Kidney Disease Across its Stages. 2015 , 43-54		
618	The Interdisciplinary Chronic Kidney Disease Clinic. 2015 , 587-597		
617	Slowing Progression of Chronic Kidney Disease. 2015 , 598-612		1
616	Albuminuria. 2015 , 663-673		1
615	SPRINTing towards trials of blood pressure reduction to reduce CKD progression?. 2016 , 2, 229-230		1
614	Timeline of History of Hypertension Treatment. <i>Frontiers in Cardiovascular Medicine</i> , 2016 , 3, 3	5.4	43
613	Hypertension: Implications of Current JNC 8 Guidelines on Treatment. 2016 , 30-49		
612	Diabetes and Hypertension: A Comparative Review of Current Guidelines. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 95-100	2.3	63
611	Endocrine Consequences of Metabolic Acidosis. 2016 , 121-130		
610	Hypertension Management in Transition: From CKD to ESRD. 2016 , 23, 255-61		7
609	Extracorporeal shock wave therapy does not improve hypertensive nephropathy. 2016 , 4, e12699		5

608	Associations Between Blood Pressure and Outcomes Among Blacks in the Jackson Heart Study. 2016 , 5,		3
607	The Role of Beta-Blockers in the Treatment of Hypertension. 2017 , 956, 149-166		24
606	Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. <i>Journal of Hypertension</i> , 2016 , 34, 1921-32	1.9	54
605	Augmented circadian rhythm of the intrarenal renin-angiotensin systems in anti-thymocyte serum nephritis rats. 2016 , 39, 312-20		16
604	Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity. 2016 , 11, 355-74		40
603	Renin-angiotensin-aldosterone system blockade in chronic kidney disease: current strategies and a look ahead. 2016 , 11, 627-35		21
602	Conservative management of chronic kidney disease stage 5: role of angiotensin converting enzyme inhibitors. 2016 , 29, 809-815		3
601	Update in Hypertension Therapy. <i>Medical Clinics of North America</i> , 2016 , 100, 665-93	7	6
600	Social Determinants of Racial Disparities in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2016 , 27, 2576-95	12.7	115
599	Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis. 2016 , 38, 849-56		8
598	Hypertension in Chronic Kidney Disease Part 1: Out-of-Office Blood Pressure Monitoring: Methods, Thresholds, and Patterns. <i>Hypertension</i> , 2016 , 67, 1093-101	8.5	40
597	Evidence-Based Policy Making: Assessment of the American Heart Association's Strategic Policy Portfolio: A Policy Statement From the American Heart Association. 2016 , 133, e615-53		24
596	Hypertension Treatment in Blacks: Discussion of the U.S. Clinical Practice Guidelines. 2016 , 59, 282-288		15
595	Renin-Angiotensin-Aldosterone System Antagonism and Polycystic Kidney Disease Progression. 2016 , 134, 59-63		5
594	Patterns of Estimated Glomerular Filtration Rate Decline Leading to End-Stage Renal Disease in Type 1 Diabetes. 2016 , 39, 2262-2269		29
593	The Patterns, Risk Factors, and Prediction of Progression in Chronic Kidney Disease: A Narrative Review. 2016 , 36, 273-82		28
592	Established and Emerging Strategies in the Treatment of Chronic Kidney Disease. 2016 , 36, 331-42		14
591	BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out?. 2016 , 18, 98		5

590 Clinical Case 4: Patient with End-Stage Renal Disease. **2016**, 61-79

589 Hypertension in Chronic Kidney Disease. **2017**, 956, 307-325 51

588 Research Needs to Improve Hypertension Treatment and Control in African Americans. *Hypertension*, **2016**, 68, 1066-1072 8.5 49

587 More Versus Less Intensive Blood Pressure-Lowering Strategy: Cumulative Evidence and Trial Sequential Analysis. *Hypertension*, **2016**, 68, 642-53 8.5 63

586 Specific Blood Pressure Targets for Patients With Diabetic Nephropathy?. **2016**, 39 Suppl 2, S228-33 12

585 Blood Pressure Targets in CKD: Lessons Learned from SPRINT and Previous Observational Studies. **2016**, 18, 88 4

584 Combined Effects of GSTM1 Null Allele and APOL1 Renal Risk Alleles in CKD Progression in the African American Study of Kidney Disease and Hypertension Trial. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 3140-3152 12.7 27

583 Diagnosis and Management of Hypertension in Children with Chronic Kidney Disease. **2016**, 299-320

582 Pathophysiological Mechanisms and Correlates of Therapeutic Pharmacological Interventions in Essential Arterial Hypertension. **2017**, 956, 37-59 7

581 Management of Hypertension in Chronic Kidney Disease. **2016**, 219-236

580 Hypertension control and care at Mulago Hospital ambulatory clinic, Kampala-Uganda. **2016**, 9, 487 9

579 Identifying the optimal blood pressure target for ideal health. **2016**, 4, 1-6 7

578 Impact of achieved systolic blood pressure on renal function in hypertensive patients. **2016**, 2, 271-276 0

577 Analysis of ABCG2 and other urate transporters in uric acid homeostasis in chronic kidney disease: potential role of remote sensing and signaling. **2016**, 9, 444-53 62

576 A scoping review of adult chronic kidney disease clinical pathways for primary care. **2017**, 32, 838-846 18

575 Obesity, Renin-Angiotensin System Blockade and Risk of Adverse Renal Outcomes: A Population-Based Cohort Study. **2016**, 43, 431-40 10

574 Going Upstream: Coordination to Improve CKD Care. **2016**, 29, 125-34 8

573 Community pharmacist targeted screening for chronic kidney disease. **2016**, 149, 13-7 13

572	Effect of Intensive Versus Usual Blood Pressure Control on Kidney Function Among Individuals With Prior Lacunar Stroke: A Post Hoc Analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) Randomized Trial. 2016 , 133, 584-91		47
571	A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever. 2016 , 44, 9-20		1
570	Hypertension-attributed nephropathy: what's in a name?. 2016 , 12, 27-36		51
569	Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials. 2016 , 31, 1425-36		23
568	How Does SPRINT (Systolic Blood Pressure Intervention Trial) Direct Hypertension Treatment Targets for CKD?. 2016 , 68, 15-8		6
567	Which Patients Does the SPRINT Study Not Apply To and What Are the Appropriate Blood Pressure Goals in These Populations?. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 477-8	2.3	6
566	Associations of antiplatelet therapy and beta blockade with patient outcomes in atherosclerotic renovascular disease. 2016 , 10, 149-158.e3		8
565	Renal function trajectory over time and adverse clinical outcomes. 2016 , 20, 379-93		8
564	Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. 2016 , 387, 957-967		1638
563	Change in Measured GFR Versus eGFR and CKD Outcomes. <i>Journal of the American Society of Nephrology: JASN</i> , 2016 , 27, 2196-204	12.7	30
562	Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician. <i>American Journal of Medicine</i> , 2016 , 129, 153-162.e7	2.4	105
561	Lupus nephritis: an update. 2016 , 20, 1-13		39
560	Management of hypertension in patients with chronic kidney disease. 2016 , 6, S6-S10		
559	Testing the trajectory difference in a semi-parametric longitudinal model. 2017 , 26, 1519-1531		3
558	Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE). 2017 , 18, 23		36
557	Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta-Analysis of Randomized Trials. <i>American Journal of Medicine</i> , 2017 , 130, 707-719.e8	2.4	105
556	The Urine Preservative Acetic Acid Degrades Urine Protein: Implications for Urine Biorepositories and the AASK Cohort Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 1394-1398	12.7	7
555	Beta-blockers for hypertension. 2017 , 1, CD002003		69

554	Persistent albuminuria as a surrogate marker of chronic kidney damage among newly diagnosed hypertensives: Prevalence and risk factors in an urban population in Karachi, Pakistan. 2017 , 39, 65-73		
553	Hypertension. 2017 , 456-471		
552	Joint Modeling of Repeated Measures and Competing Failure Events In a Study of Chronic Kidney Disease. 2017 , 9, 504-524		2
551	Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. 2017 , 389, 1035-1042		71
550	Intensive blood pressure lowering in chronic kidney disease: the time has come. 2017 , 26, 197-204		1
549	Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension. <i>Journal of Clinical Hypertension</i> , 2017 , 19, 695-701	2.3	6
548	Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 2794-2801	12.7	29
547	Preoperative Nomograms for Predicting Renal Function at 1 Year After Partial Nephrectomy. 2017 , 31, 711-718		10
546	Obesity-Associated Hypertension: the Upcoming Phenotype in African-American Women. <i>Current Hypertension Reports</i> , 2017 , 19, 41	4.7	6
545	Management of Hypertension in Patients with Chronic Kidney Disease. <i>Current Hypertension Reports</i> , 2017 , 19, 43	4.7	16
544	Comparative efficacy of β -blockers on mortality and cardiovascular outcomes in patients with hypertension: a systematic review and network meta-analysis. 2017 , 11, 394-401		16
543	Effects of Intensive BP Control in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 2812-2823	12.7	234
542	Comparative Effect of Calcium Channel Blockers on Glomerular Function in Hypertensive Patients with Diabetes Mellitus. 2017 , 17, 403-412		4
541	[Blood pressure targets in nephrology in 2017]. 2017 , 13 Suppl 1, S69-S74		
540	Cumulative in-trial and post-trial effects of blood pressure and lipid lowering: systematic review and meta-analysis. <i>Journal of Hypertension</i> , 2017 , 35, 905-913	1.9	12
539	Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease. 2017 , 20, 715-722		0
538	Urine Ammonium Predicts Clinical Outcomes in Hypertensive Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 2483-2490	12.7	39
537	In the Wake of Systolic Blood Pressure Intervention Trial: New Targets for Improving Hypertension Management in Chronic Kidney Disease?. 2017 , 135, 287-290		2

536	The use of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations. 2017 , 129, 421-429		0
535	Time-Varying Association of Individual BP Components with eGFR in Late-Stage CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 904-911	6.9	4
534	Association of Intensive Blood Pressure Control and Kidney Disease Progression in Nondiabetic Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis. 2017 , 177, 792-799		66
533	Clinical utility of sympathetic blockade in cardiovascular disease management. 2017 , 15, 277-288		7
532	Precision Medicine for Hypertension Management in Chronic Kidney Disease: Relevance of SPRINT for Therapeutic Targets in Nondiabetic Renal Disease. 2017 , 33, 611-618		5
531	Strict blood pressure control associates with decreased mortality risk by APOL1 genotype. 2017 , 91, 443-450		23
530	Urine and serum midkine levels in an Australian chronic kidney disease clinic population: an observational study. 2017 , 7, e014615		4
529	Chronic Kidney Disease and BP Goals. 2017 , 403-409		
528	Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. 2017 , 10, CD010315		11
527	Cigarette Smoking Attenuates Kidney Protection by Angiotensin-Converting Enzyme Inhibition in Nondiabetic Chronic Kidney Disease. 2017 , 46, 260-267		12
526	Prevalence and Outcomes of Left-Sided Valvular Heart Disease Associated With Chronic Kidney Disease. 2017 , 6,		37
525	Relationship Between Visit-to-Visit Blood Pressure Variability (BPV) and Kidney Function in Patients with Hypertension. 2017 , 42, 697-707		7
524	Risk Variants, Incident Proteinuria, and Subsequent eGFR Decline in Blacks with Hypertension-Attributed CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 1771-1777	6.9	16
523	Current View on CKD Risk Factors: Traditional, Noncommunicable Diseases Diabetes, Hypertension, and Obesity. 2017 , 183-190		1
522	Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure: overview and meta-analyses of randomized trials. <i>Journal of Hypertension</i> , 2017 , 35, 2138-2149	1.9	13
521	Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis. 2017 , 177, 1498-1505		98
520	BP Targets in CKD, Mortality, and SPRINT: What Have We Learned?. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 2561-2563	12.7	4
519	The Elusive Search for Optimal Blood Pressure Targets. <i>Current Hypertension Reports</i> , 2017 , 19, 63	4.7	2

518	Refining the Policy for Timing of Kidney Transplant Waitlist Qualification. 2017 , 3, e195		2
517	Blood pressure and the risk of chronic kidney disease progression using multistate marginal structural models in the CRIC Study. 2017 , 36, 4167-4181		5
516	The Effect of CPAP Therapy on Resistant Hypertension in Obstructive Sleep Apnea Syndrome Patients with Chronic Kidney Disease. 2017 , 323-332		
515	Some Thoughts About Racial Disparities. 2017 , 37, 641-645		
514	Antihypertensive medications and risk of death and hospitalizations in US hemodialysis patients: Evidence from a cohort study to inform hypertension treatment practices. 2017 , 96, e5924		13
513	Effectiveness of patiomer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics. <i>Journal of Hypertension</i> , 2017 , 35 Suppl 1, S57-S63	1.9	18
512	The effect of vasodilator β blockers on renal function in hypertensive patients. <i>Journal of Hypertension</i> , 2017 , 35, 1768-1777	1.9	1
511	Blood pressure and age-related GFR decline in the general population. 2017 , 18, 77		16
510	Renin-angiotensin II-aldosterone system blockers and time to renal replacement therapy in children with CKD. 2017 , 32, 643-649		18
509	Associations of Conventional Echocardiographic Measures with Incident Heart Failure and Mortality: The Chronic Renal Insufficiency Cohort. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 60-68	6.9	21
508	BP Control and Long-Term Risk of ESRD and Mortality. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 671-677	12.7	57
507	The Case for Low Blood Pressure Targets. <i>American Journal of Hypertension</i> , 2017 , 30, 3-7	2.3	5
506	Targeted disruption of Cd40 in a genetically hypertensive rat model attenuates renal fibrosis and proteinuria, independent of blood pressure. 2017 , 91, 365-374		12
505	The Kidney in Hypertension. <i>Medical Clinics of North America</i> , 2017 , 101, 207-217	7	19
504	The impact of antihypertensives on kidney disease. 2017 , 6, 611		3
503	RAAS Blockade as First-Line Antihypertensive Therapy among People with CKD. 2017 ,		
502	Annual deterioration of renal function in hypertensive patients with and without diabetes. 2017 , 13, 231-237		9
501	Peripheral and Cerebral Resistance Arteries in the Spontaneously Hypertensive Heart Failure Rat: Effects of Stilbenoid Polyphenols. 2017 , 22,		4

500	A Classification Model to Predict the Rate of Decline of Kidney Function. <i>Frontiers in Medicine</i> , 2017 , 4, 97	4.9	6
499	Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis. 2017 , 12, e0188975		18
498	Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients. 2017 , 18, 342		21
497	FimAsartaN proTeinuriA SusTained reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial. 2017 , 18, 632		2
496	Target goal blood pressure in hypertension management. 2017 , 60, 819		1
495	Drug Discovery in Tissue Fibrosis. 2017 , 694-713		0
494	OBJETIVOS TERAPÉUTICOS EN HIPERTENSIÓN ARTERIAL: METAS DE PRESIÓN ARTERIAL EN LOS DIVERSOS SUBGRUPOS DE HIPERTENSOS. 2018 , 29, 21-32		1
493	Resistant and undertreated hypertension in patients with chronic kidney disease: data from the PATRIOTIC survey. 2018 , 40, 784-791		2
492	Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?. 2018 , 72, 728-744		33
491	Improvement of Blood Pressure Control in Renal Transplant Recipients-Retrospective Longitudinal Study. <i>Transplantation Proceedings</i> , 2018 , 50, 155-159	1.1	3
490	Hypertension in Chronic Kidney Disease. 2018 , 451-472		
489	Valsartan Effective for Malignant Hypertension after Aortic Dissection with Renal Artery Involvement. 2018 , 38, e25-e28		1
488	[What is the goal blood pressure in non-diabetic chronic kidney disease?]. 2018 , 14, 446-453		
487	Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 694-702	2.3	7
486	Target blood pressure and kidney protection. 2018 , 6, 521-523		4
485	Preventive Cardiology. 2018 , 269-289		
484	Stroke volume and proteinuria in obesity-related glomerulopathy: potential role in pathogenesis and choice of antihypertensive regimen. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 819-820	2.3	
483	Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab. 2018 , 81, 1051-1059		6

482	Single-Pill Combinations in the Treatment of Hypertension in Adults: Beyond Convenience. 2018 , 42, 205-208		1
481	Antihypertensive therapy in nondiabetic chronic kidney disease: a review and update. 2018 , 12, 154-181		5
480	Initial Treatment of Hypertension. 2018 , 378, 636-644		28
479	Implications of the New National Guidelines for Hypertension. 2018 , 26, 55-61		3
478	Renal Considerations in the Treatment of Hypertension. <i>American Journal of Hypertension</i> , 2018 , 31, 394-401	2-3	5
477	Hypertension. 2018 , 315-358		
476	Revisiting RAAS blockade in CKD with newer potassium-binding drugs. 2018 , 93, 325-334		42
475	Chronic kidney disease and stroke: more observations but no trials. 2018 , 33, 367-370		2
474	Considerations for Optimal Blood Pressure Goals in the Elderly Population: A Review of Emergent Evidence. 2018 , 38, 370-381		4
473	Unsweetening the Heart: Possible Pleiotropic Effects of SGLT2 Inhibitors on Cardio and Cerebrovascular Alterations in Resistant Hypertensive Subjects. <i>American Journal of Hypertension</i> , 2018 , 31, 274-280	2-3	3
472	Diastolic blood pressure and risk profile in renal and cardiovascular diseases. Results from the SPRINT trial. 2018 , 12, 513-523.e3		16
471	More From SPRINT (Systolic Blood Pressure Intervention Trial): A Closer Look at the Price of Intensive Blood Pressure Control. 2018 , 71, 611-614		1
470	Contemporary Drug Treatment of Hypertension: Focus on Recent Guidelines. 2018 , 78, 567-576		6
469	Blood pressure parameters and morbid and mortal outcomes in nondialysis-dependent chronic kidney disease. 2018 , 27, 16-22		1
468	BP Measurement in Clinical Practice: Time to SPRINT to Guideline-Recommended Protocols. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 383-388	12.7	18
467	Impact of achieved blood pressure on renal function decline and first stroke in hypertensive patients with chronic kidney disease. 2018 , 33, 409-417		11
466	Urine Anion Gap to Predict Urine Ammonium and Related Outcomes in Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018 , 13, 205-212	6.9	11
465	Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). 2018 , 71, 352-361		75

464	Longitudinal Weight Change During CKD Progression and Its Association With Subsequent Mortality. 2018 , 71, 657-665		34
463	BP in Dialysis: Results of a Pilot Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 307-316	12.7	35
462	Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy. 2018 , 71, 91-101		38
461	Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association		84
460	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018 , 71, 2100-2339		462
459	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018 , 71, 2100-2339		2178
458	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018 , 71, 2100-2339	8.5	1567
457	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018 , 71, 2100-2339	8.5	1505
456	Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i> , 2018 , 71, e116-e135	8.5	80
455	Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis. 2018 , 178, 28-36		192
454	Blood Pressure Variability Predicts Adverse Events and Cardiovascular Outcomes in Chronic Kidney Disease: A Post-Hoc Analysis of the SPRINT Trial. <i>American Journal of Hypertension</i> , 2017 , 31, 48-52	2.3	15
453	Use of Combination Therapies. 2018 , 261-267		
452	Antihypertensive drug therapy. 2018 , 6, 123		1
451	First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. 2018 , 11, CD008170		10
450	Prevalence and progression of diabetic nephropathy in South Asian, white European and African Caribbean people with type 2 diabetes: A systematic review and meta-analysis. 2019 , 21, 658-673		7
449	Evaluation of Surrogate End Points for Progression to ESKD: Necessary and Challenging. 2018 , 72, 771-773		4
448	The effect of model selection on cost-effectiveness research: a comparison of kidney function-based microsimulation and disease grade-based microsimulation in chronic kidney disease modeling. 2018 , 18, 94		4
447	Risk Stratification and Treatment of Coronary Disease in Chronic Kidney Disease and End-Stage Kidney Disease. 2018 , 38, 582-599		13

446	Racial/ethnic differences in hypertension prevalence: Public health impact versus clinical importance of baseline data of the HELIUS study. 2018 , 25, 1911-1913		0
445	Antihypertensive Drug Therapy in Patients of African and South Asian Ethnicity: A Systematic Review. 2018 , 243-269		
444	Nrf2 activator for the treatment of kidney diseases. 2018 , 360, 30-37		38
443	Antihypertensive treatment and renal protection: Is there a J-curve relationship?. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 1560-1574	2.3	12
442	Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. 2018 , 7, e009992		16
441	Hypertension Treatment Effects on Orthostatic Hypotension and Its Relationship With Cardiovascular Disease. <i>Hypertension</i> , 2018 , 72, 986-993	8.5	20
440	Applying the new intensive blood pressure categories to a nondialysis chronic kidney disease population: the Prevalence, Awareness and Treatment Rates in Chronic Kidney Disease Patients with Hypertension in China survey. 2020 , 35, 155-161		3
439	The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. 2018 , 11, 749-761		120
438	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018 , 138, e426-e483		397
437	Kidney Damage Biomarkers and Incident Chronic Kidney Disease During Blood Pressure Reduction: A Case-Control Study. 2018 , 169, 610-618		39
436	Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 2010-2019	27.4	45
435	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018 , 138, e595-e616		242
434	Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018 , 138, e595-e616		45
433	Peripheral Adrenergic Blockers. 2018 , 222-229		
432	APOL1-Associated Nephropathy: A Key Contributor to Racial Disparities in CKD. 2018 , 72, S8-S16		71
431	SPRINT and the Kidney: What Have We Learned?. <i>Current Hypertension Reports</i> , 2018 , 20, 95	4.7	1
430	Updated American Heart Association/American College of Cardiology; European Society of Hypertension/European Society of Cardiology Guidelines. 2018 , 459-468		1
429	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018 , 138, e426-e483		83

428	Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report. 2018 , 72, 873-884		35
427	Serum 6-Bromotryptophan Levels Identified as a Risk Factor for CKD Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 1939-1947	12.7	10
426	A Review of ACE Inhibitors and ARBs in Black Patients With Hypertension. 2018 , 52, 1143-1151		25
425	Quantifying and estimating the predictive accuracy for censored time-to-event data with competing risks. 2018 , 37, 3106-3124		6
424	Detection of Atherosclerotic Cardiovascular Disease in Patients with Advanced Chronic Kidney Disease in the Cardiology and Nephrology Communities. 2018 , 8, 285-295		4
423	Renin Angiotensin Aldosterone System Blockers. 2018 , 230-241		1
422	Calcium Channel Blockers. 2018 , 242-253		1
421	Hypertension and Chronic Kidney Disease. 2018 , 311-320		
420	Kidney Response to the Spectrum of Diet-Induced Acid Stress. 2018 , 10,		6
419	Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). 2018 , 10,		19
418	Blood pressure variability predicts adverse events and cardiovascular outcomes in SPRINT. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 1247-1252	2.3	20
417	Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. 2018 , 7, CD010315		16
416	Crossroads of metabolism and CKD. 2018 , 94, 242-243		3
415	Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trial (SPRINT): A Randomized Clinical Trial. <i>American Journal of Hypertension</i> , 2017 , 31, 97-107	2.3	22
414	Clinical and metabolomic risk factors associated with rapid renal function decline in sickle cell disease. 2018 , 93, 1451-1460		17
413	The Validity of Drug Effects on Proteinuria, Albuminuria, Serum Creatinine, and Estimated GFR as Surrogate End Points for ESKD: A Systematic Review. 2018 , 72, 779-789		9
412	Determining the Optimal Systolic Blood Pressure for Hypertensive Patients: A Network Meta-analysis. 2018 , 34, 1581-1589		6
411	Treatment of Hypertension in Chronic Kidney Disease. <i>Current Hypertension Reports</i> , 2018 , 20, 64	4.7	16

410 Clinical management of chronic kidney disease. **2019**, 162-168

409 Primary hypertension. **2019**, 429-437

408 Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis. **2019**, 28, 358-374 6

407 2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations. **2019**, 25, 19 18

406 2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. **2019**, 25, 20 110

405 Optimal diastolic blood pressure range in intensive systolic targets: Resolving the controversy between observational and intention-to-treat analyses. *Journal of Clinical Hypertension*, **2019**, 21, 919-927^{2,3}

404 Effect of Blood Pressure Control on Long-Term Risk of End-Stage Renal Disease and Death Among Subgroups of Patients With Chronic Kidney Disease. **2019**, 8, e012749 15

403 The Kidney in Hypertension. **2019**, 191-210

402 Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data. *Journal of the American Society of Nephrology: JASN*, **2019**, 30, 1746-1755 12.7 49

401 Extracellular vesicles as a novel diagnostic and research tool for patients with HTN and kidney disease. **2019**, 317, F641-F647 9

400 Hipertensi3 arterial en la enfermedad renal cr3nica. **2019**, 12, 4772-4778 1

399 Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation. *Journal of the American Society of Nephrology: JASN*, **2019**, 30, 1756-1769^{12.7} 31

398 Hypertension Management in Chronic Kidney Disease and Diabetes: Lessons from the Systolic Blood Pressure Intervention Trial. **2019**, 37, 307-317 6

397 More Evidence to Suggest a Relation of Blood Pressure to Long-term Progression of Kidney Disease: Is It Causal?. **2019**, 74, 293-296 1

396 The Use of Renin-Angiotensin System Inhibitors in Patients With Chronic Kidney Disease. **2019**, 35, 1220-1227 9

395 Treatment of Hypertension in Chronic Kidney Disease. **2019**, 239-255

394 APOL1 and kidney cell function. **2019**, 317, F463-F477 11

393 The Impact of APOL1 on Chronic Kidney Disease and Hypertension. **2019**, 26, 131-136 6

392	Does Chronic Kidney Disease Predict Stroke Risk Independent of Blood Pressure?: A Systematic Review and Meta-Regression. 2019 , 50, 3085-3092		22
391	Risk of end-stage renal disease in patients with hypertrophic cardiomyopathy: A nationwide population-based cohort study. 2019 , 9, 14565		11
390	Genetics and ESKD Disparities in African Americans. 2019 , 74, 811-821		23
389	Hypertension in Premenopausal and Postmenopausal Women. <i>Current Hypertension Reports</i> , 2019 , 21, 74	4.7	12
388	Does the temporary decrease in the estimated glomerular filtration rate (eGFR) after initiation of mineralocorticoid receptor (MR) antagonist treatment lead to a long-term renal protective effect?. 2019 , 42, 1841-1847		7
387	GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. <i>Journal of the American Society of Nephrology: JASN</i> , 2019 , 30, 1735-1745	12.7	68
386	Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers. 2019 , 14, e0221957		5
385	The role of chronic kidney disease-associated dysbiosis in cardiovascular disease. 2019 , 244, 514-525		15
384	1,2,3,4,6-Penta-O-galloyl- β -D-glucose modulates perivascular inflammation and prevents vascular dysfunction in angiotensin II-induced hypertension. 2019 , 176, 1951-1965		13
383	International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people. 2019 , 15, 713-726		37
382	Nephropathy Progression in African Americans With a Family History of ESKD: Implications for Clinical Trials in APOL1-Associated Nephropathy. 2019 , 74, 284-286		2
381	Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50. 2019 , 85, 2218-2227		5
380	Association of Blood Pressure and Risk of Cardiovascular and Chronic Kidney Disease in Hong Kong Hypertensive Patients. <i>Hypertension</i> , 2019 , 74, 331-340	8.5	15
379	Acid Load, and CKD Progression. <i>Kidney International Reports</i> , 2019 , 4, 946-954	4.1	2
378	Trends in Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use among Those with Impaired Kidney Function in the United States. <i>Journal of the American Society of Nephrology: JASN</i> , 2019 , 30, 1314-1321	12.7	29
377	APOL1 high-risk genotypes and renal transplantation. 2019 , 33, e13582		4
376	Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. 2019 , 96, 1030-1036		15
375	How Low Do We Go (in the Post-SPRINT Era)?. 2019 , 26, 110-116		

374	Hypertension: A Common but Complex Condition. 2019 , 26, 85-86		
373	Mortality Outcomes With Intensive Blood Pressure Targets in Chronic Kidney Disease Patients. <i>Hypertension</i> , 2019 , 73, 1275-1282	8.5	19
372	Magnitude of the Difference Between Clinic and Ambulatory Blood Pressures and Risk of Adverse Outcomes in Patients With Chronic Kidney Disease. 2019 , 8, e011013		8
371	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 140, e596-e646		898
370	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 74, 1376-1414		463
369	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 74, e177-e232		516
368	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 140, e563-e595		192
367	Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trials. 2019 , 42, 469-482		16
366	Supported Palladium Nanoparticles that Catalyze Aminocarbonylation of Aryl Halides with Amines using Oxalic Acid as a Sustainable CO Source. 2019 , 25, 4067-4071		20
365	Renin-angiotensin system inhibition in advanced chronic kidney disease: how low can the kidney function go?. 2019 , 28, 171-177		4
364	Management of Hypertension in Chronic Kidney Disease. 2019 , 79, 365-379		75
363	Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment. 2019 , 9, e028438		3
362	Association of Blood Pressure at Specific Time-Points with 1-Year Renal Outcomes in Patients with Diabetic Chronic Kidney Disease. 2019 , 17, 36-44		
361	Prevalence Of Anemia And Its Associated Factors Among Chronic Kidney Disease Patients At University Of Gondar Hospital, Northwest Ethiopia: A Hospital-Based Cross Sectional Study. 2019 , 12, 219-228		8
360	Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Hypertension</i> , 2019 , 37, 2307-2324	1.9	36
359	The incessant search for renal biomarkers: is it really justified?. 2019 , 28, 195-202		3
358	Heart Failure and Changes in Kidney Function: Focus on Understanding, Not Reacting. 2019 , 15, 455-461		3
357	[Austrian Consensus on High Blood Pressure 2019]. 2019 , 131, 489-590		3

356	Hypertension in Cancer Patients and Survivors: Epidemiology, Diagnosis, and Management. 2019 , 1, 238-251		32
355	Outcomes of minority patients with very severe hypertension (>220/>120 mmHg). <i>Journal of Hypertension</i> , 2019 , 37, 415-425	1.9	1
354	Serious adverse events in patients with target-oriented blood pressure management: a systematic review. <i>Journal of Hypertension</i> , 2019 , 37, 2135-2144	1.9	7
353	Chronic Kidney Disease in the Elderly. 2019 , 73-86.e5		
352	The Pediatric Patient With Chronic Kidney Disease. 2019 , 87-104.e8		
351	Impact of Recent Clinical Trials on Nephrology Practice: Are We in a Stagnant Era?. 2019 , 5, 69-80		9
350	Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 757-764	6.9	31
349	A feared combination: Hypertension and chronic kidney disease. <i>Journal of Clinical Hypertension</i> , 2019 , 21, 102-104	2.3	3
348	Hypertension Management in African Americans: The AASK and Other Landmark Trial Application. 2019 , 145-154		
347	Blood Pressure Goals in Patients with CKD: A Review of Evidence and Guidelines. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 161-169	6.9	25
346	Hypertensive Chronic Kidney Disease. 2019 , 62-72.e6		
345	Shake Rattle & Roll - Design and rationale for a pragmatic trial to improve blood pressure control among blacks with persistent hypertension. 2019 , 76, 85-92		7
344	Wearable Devices for Precision Medicine and Health State Monitoring. 2019 , 66, 1242-1258		48
343	Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT. 2019 , 73, 21-30		62
342	The effect of interactions between proteinuria, activity of fibroblast growth factor 23 and serum phosphate on renal progression in patients with chronic kidney disease: a result from the KoreaN cohort study for Outcome in patients With Chronic Kidney Disease study. 2020 , 35, 438-446		3
341	Chronic kidney disease in low-middle income populations: a call to action for screening and prevention-comment. 2020 , 15, 155-156		
340	Pathophysiology of Hypertension in Chronic Kidney Disease. 2020 , 313-322		0
339	Clinical Assessment and Management of Chronic Kidney Disease Across Its Stages. 2020 , 55-71		

338	Slowing Progression of Chronic Kidney Disease. 2020 , 937-959		2
337	The Interdisciplinary Clinic for Chronic Kidney Disease. 2020 , 921-935		
336	Approach to the Patient with Hypertensive Nephrosclerosis. 2020 , 737-752		1
335	Prevention and treatment of stroke in patients with chronic kidney disease: an overview of evidence and current guidelines. 2020 , 97, 266-278		17
334	Hypertension management in chronic kidney disease. 2021 , 36, 2194-2195		1
333	Sodium Excretion and Cardiovascular Outcomes in African American Patients With CKD: Findings From the African American Study of Kidney Disease and Hypertension. 2020 , 2, 80-82		2
332	Novel dietary and pharmacologic approaches for acid-base modulation to preserve kidney function and manage uremia. 2020 , 29, 39-48		2
331	Update on hypertension in African-Americans. 2020 , 63, 33-39		12
330	Blockers: Their new life from hypertension to cancer and migraine. 2020 , 151, 104587		20
329	[HTA in France: And nephrologists?]. 2020 , 16, 345-346		
328	[Impaired hypertension control in France: What the nephrologist needs to know]. 2020 , 16, 347-352		0
327	Group-Based Care in Adults and Adolescents With Hypertension and CKD: A Feasibility Study. 2020 , 2, 317-325		0
326	Intensive Blood Pressure Lowering Should Be the Goal for Most Individuals at High Risk of Cardiovascular Disease Irrespective of Albuminuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020 , 15, 1081-1083		6.9
325	Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension?. 2020 , 22, 95		11
324	Practical Strategy for Treating Chronic Kidney Disease (CKD)-Associated with Hypertension. 2020 , 13, 171-178		0
323	Intensive BP Control and eGFR Declines: Are These Events Due to Hemodynamic Effects and Are Changes Reversible?. 2020 , 22, 117		2
322	Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials. <i>Journal of Hypertension</i> , 2020 , 38, 1669-1681	1.9	17
321	MMRM vs joint modeling of longitudinal responses and time to study drug discontinuation in clinical trials using a "de jure" estimand. 2020 , 19, 909-927		2

320	Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. 2020 , 10, CD007004		16
319	Association between serum 25-hydroxyvitamin D and the effects of Angiotensin II receptor blocker on renal function among African Americans: A post hoc analysis of a randomized placebo-controlled trial. <i>Journal of Clinical Hypertension</i> , 2020 , 22, 1874-1883	2.3	1
318	Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. 2020 , 9, CD010315		7
317	Renal outcomes of treatment with telmisartan in patients with stage 3-4 chronic kidney disease: A prospective, randomized, controlled trial (JINNAGA). 2020 , 8, 2050312120973502		
316	Blood pressure targets in adults with hypertension. 2020 , 12, CD004349		3
315	Agreement Between Administrative Database and Medical Chart Review for the Prediction of Chronic Kidney Disease G category. <i>Canadian Journal of Kidney Health and Disease</i> , 2020 , 7, 20543581209559908 ⁶	2.3	6
314	Factors Associated With Failure to Achieve the Intensive Blood Pressure Target in the Systolic Blood Pressure Intervention Trial (SPRINT). <i>Hypertension</i> , 2020 , 76, 1725-1733	8.5	4
313	Blood pressure target for hypertension in chronic kidney disease: One size does not fit all. <i>Journal of Clinical Hypertension</i> , 2020 , 22, 929-932	2.3	3
312	Managing Hypertension in the elderly: What's new?. 2020 , 1, 100001		2
311	Dynamic prediction of competing risk events using landmark sub-distribution hazard model with multiple longitudinal biomarkers. 2020 , 29, 3179-3191		2
310	Kidney Disease, Race, and GFR Estimation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020 , 15, 1203-1212	6.9	72
309	Increased Proteinuria is Associated with Increased Aortic Arch Calcification, Cardio-Thoracic Ratio, Rapid Renal Progression and Increased Overall and Cardiovascular Mortality in Chronic Kidney Disease. 2020 , 17, 1102-1111		3
308	Blood pressure targets in patients with chronic kidney disease: A critical evaluation of clinical-trial evidence and guideline recommendations. <i>Journal of Clinical Hypertension</i> , 2020 , 22, 924-928	2.3	4
307	Achieving blood pressure control targets in hypertensive patients of rural China - a pilot randomized trial. 2020 , 21, 515		0
306	Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study). <i>Kidney International Reports</i> , 2020 , 5, 879-890	4.1	37
305	Review - current opinion in cardiology hypertension in chronic kidney disease. 2020 , 35, 360-367		2
304	Blood pressure targets in patients with chronic kidney disease: MDRD and AASK now confirming SPRINT. 2020 , 13, 287-290		4
303	Community pharmacist identification of chronic kidney disease using point-of-care technology: A pilot study. 2020 , 153, 84-87		0

302	Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES). 2020 , 158, 123-129	2
301	Managing the elderly patient with hypertension: current strategies, challenges, and considerations. 2020 , 18, 117-125	0
300	Oxidant stress and renal function among children with chronic kidney disease: a repeated measures study. 2020 , 10, 3129	4
299	Copper-catalysed synthesis of 3-hydroxyisoindolin-1-ones from benzylcyanide 2-iodobenzamides. 2020 , 18, 988-998	5
298	Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care. 2020 , 22, 847-856	5
297	Impacts of center and clinical factors in antihypertensive medication use after kidney transplantation. 2020 , 34, e13803	1
296	Treatment resistant hypertension among ambulatory hypertensive patients: A cross sectional study. 2020 , 15, e0232254	0
295	Toward Causally Interpretable Meta-analysis: Transporting Inferences from Multiple Randomized Trials to a New Target Population. 2020 , 31, 334-344	14
294	Association Between APOL1 Genotype and Need for Kidney Replacement Therapy in Patients Without Diabetes: Does Age Matter?. 2020 , 75, 294-296	1
293	Blood pressure targets and pharmacotherapy for hypertensive patients on hemodialysis. 2020 , 21, 1219-1240	0
292	Tubular secretion of creatinine and kidney function: an observational study. 2020 , 21, 108	8
291	Blood pressure after treatment with sodium-glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score-matched models. 2021 , 12, 74-81	4
290	SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives. 2021 , 35, 12-25	12
289	When should we start and stop ACEi/ARB in paediatric chronic kidney disease?. 2021 , 36, 1751-1764	1
288	Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension : A Systematic Review and Individual Participant-based Meta-analysis. 2021 , 174, 58-68	15
287	Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. 2021 , 99, 999-1009	23
286	Hypertension in Chronic Kidney Disease (CKD): Diagnosis, Classification, and Therapeutic Targets. <i>American Journal of Hypertension</i> , 2021 , 34, 318-326	2.3 4
285	Impact of pharmacist intervention for blood pressure control in patients with chronic kidney disease: A meta-analysis of randomized clinical trials. 2021 , 46, 114-120	4

284	Race, APOL1 Risk Variants, and Clinical Outcomes among Older Adults: The ARIC Study. 2021 , 69, 155-163		0
283	Major adverse renal events (MARE): a proposal to unify renal endpoints. 2021 , 36, 491-497		9
282	Identifying Clinical and Genomic Features Associated With Chronic Kidney Disease. 2020 , 3, 528828		0
281	Social determinants of racial and socioeconomic disparities in CKD and ESRD. 2021 , 49-88		0
280	Subtyping CKD Patients by Consensus Clustering: The Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 639-653	12.7	10
279	Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome. 2021 , 52, 180-189		11
278	How Do I Manage Hypertension in Patients with Advanced Chronic Kidney Disease Not on Dialysis? Perspectives from Clinical Practice. 2021 , 17, 1-11		1
277	Roselle: Production, Product Development, and Composites. 2021 , 1-23		1
276	Functional roles of fish collagen peptides on bone regeneration. 2021 , 40, 1295-1302		0
275	Preventive Cardio-Oncology: Cardiovascular Disease Prevention in Cancer Patients and Survivors. 2021 , 23, 1		1
274	Kidney Allograft Fibrosis: Diagnostic and Therapeutic Strategies. 2021 , 105, e114-e130		0
273	Association between antihypertensive treatment and adverse events: systematic review and meta-analysis. 2021 , 372, n189		7
272	Therapeutic Insights in Chronic Kidney Disease Progression. <i>Frontiers in Medicine</i> , 2021 , 8, 645187	4.9	12
271	Effectiveness of integrated care on delaying chronic kidney disease progression in rural communities of Thailand (ESCORT-2) trials. 2021 , 26, 333-340		2
270	[¿C�mo tratar la hipertensi�n arterial sist�lica? Estrategias de tratamiento actuales]. 2021 , 91, 493-499		0
269	L-type calcium channel blocker use and proteinuria among children with chronic kidney diseases. 2021 , 36, 2411-2419		4
268	Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease: A Difficult Equation. 2021 , 21, 619-627		1
267	KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. 2021 , 99, S1-S87		126

266	Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. 2021 , 99, 559-569		51
265	Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction. 2021 , 35, 499-509		3
264	Targeting of uncontrolled hypertension in the emergency department (TOUCHED): Design of a randomized controlled trial. 2021 , 102, 106283		
263	Examining the Role of Novel CKD Therapies for the ADPKD Patient.. <i>Kidney360</i> , 2021 , 2, 1036-1041	1.8	1
262	Assessment of Acute Kidney Injury and Longitudinal Kidney Function After Hospital Discharge Among Patients With and Without COVID-19. 2021 , 4, e211095		44
261	The Role of the Renin-Angiotensin-Aldosterone System in Cardiovascular Disease: Pathogenetic Insights and Clinical Implications.		
260	JCS 2018 Guideline on Diagnosis of Chronic Coronary Heart Diseases. 2021 , 85, 402-572		11
259	Association of Blood Pressure Genetic Risk Score with Cardiovascular Disease and CKD Progression: Findings from the CRIC Study.. <i>Kidney360</i> , 2021 , 2, 1251-1260	1.8	2
258	Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. 2021 , 22, 558-570		15
257	On-treatment blood pressure and long-term outcomes in chronic kidney disease. 2021 ,		2
256	Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study. 2021 , 77, 719-729.e1		8
255	Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: A Milestone Achieved. <i>Hypertension</i> , 2021 , 77, 1442-1455	8.5	4
254	Current Guidelines for the Treatment of Arterial Hypertension in Patients with Diabetes Mellitus and Chronic Kidney Disease. 2021 , 17, 323-331		
253	Use of renin-angiotensin-aldosterone system blockade in controversial chronic kidney disease populations. 2021 , 156, 561-567		
252	Use of renin-angiotensin-aldosterone system blockade in controversial chronic kidney disease populations. 2021 , 156, 561-567		0
251	Intensive Home Blood Pressure Lowering in Advanced Chronic Kidney Disease: A Pilot Randomized Controlled Trial Protocol. Volume 13, 21-29		
250	Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies. 2021 , 81, 1467-1489		1
249	Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2. <i>Kidney International Reports</i> , 2021 , 6, 1775-1787	4.1	26

248	Biomarkers of Immune Activation and Incident Kidney Failure With Replacement Therapy: Findings From the African American Study of Kidney Disease and Hypertension. 2021 , 78, 75-84.e1		3
247	Association of blood pressure and renal outcome in patients with chronic kidney disease; a post hoc analysis of FROM-J study. 2021 , 11, 14990		0
246	Elabela Protects Spontaneously Hypertensive Rats From Hypertension and Cardiorenal Dysfunctions Exacerbated by Dietary High-Salt Intake. 2021 , 12, 709467		0
245	Effectiveness and Tolerability of Nifedipine GITS in Patients with Chronic Kidney Disease and Uncontrolled Hypertension: A Prospective, Multicenter, Observational Study (ADRENAL). 2021 , 38, 4771-4785		1 ¹
244	Handgrip strength as a predictor of incident hypertension in the middle-aged and older population: The TCLSIH cohort study. 2021 , 150, 7-13		0
243	Association of Apparent Treatment-Resistant Hypertension With Differential Risk of End-Stage Kidney Disease Across Racial Groups in the Million Veteran Program. <i>Hypertension</i> , 2021 , 78, 376-386	8.5	1
242	Association of Blood Pressure With the Progression of CKD: Findings From KNOW-CKD Study. 2021 , 78, 236-245		6
241	Clinical epidemiological analysis of cohort studies investigating the pathogenesis of kidney disease. 2021 , 1		
240	A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease. 2021 , 81, 1491-1511		6
239	Commentary on the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD. 2021 , 23, 132		0
238	Blood pressure management and renal protection: Revisiting hypertensive nephropathy. 2021 , 84, 911-916		0
237	Nonatherosclerotic Vascular Abnormalities Associated with Chronic Kidney Disease. 2021 , 39, 415-425		
236	Management of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice Guideline. 2021 , 174, 1270-1281		11
235	Projection of the health and economic impacts of Chronic kidney disease in the Chilean population. 2021 , 16, e0256680		0
234	SPRINT-A Kidney-Centric Narrative Review: Recent Advances in Hypertension. <i>Hypertension</i> , 2021 , 78, 946-954	8.5	0
233	Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling. 2021 , 321, F548-F557		2
232	Preventive Cardiology. 2022 , 341-375		
231	Prevention of Chronic Renal Diseases in the Elderly. 2008 , 231-255		1

230	Review of Heart Failure Management in African-Americans. 2015 , 277-286	1
229	Hypertension in Chronic Kidney Disease. 2004 , 371-387	12
228	Blood Pressure Control and Primary Prevention of Stroke: Summary of Clinical Trial Data. 2011 , 41-59	1
227	Home (Self) Monitoring of Blood Pressure. 2016 , 15-43	1
226	Management of Chronic Kidney Disease. 2009 , 1661-1692	10
225	Hypertension Drug Therapy. 2020 , 1177, 149-268	3
224	The CKiD study: overview and summary of findings related to kidney disease progression. 2021 , 36, 527-538	11
223	Kidney Disease and Hypertension. 2007 , 607-619	6
222	Pathophysiology of Hypertension. 2005 , 29-38	1
221	Renal Protection in Chronic Kidney Disease. 2005 , 281-294	1
220	The Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC). 2005 , 325-339	2
219	Management of Hypertension in Black Populations. 2005 , 587-595	5
218	Risk Factors and Chronic Kidney Disease. 2011 , 758-781	1
217	Adaptation to Nephron Loss and Mechanisms of Progression in Chronic Kidney Disease. 2011 , 1918-1971	4
216	[Principal conclusions of the Argentine Consensus on Arterial Hypertension]. 2019 , 36, 96-109	4
215	Particularités et modalités de la prise en charge de l'hypertension artérielle dans les pays d'Afrique subsaharienne. 2011 , 195, 1269-1283	1
214	Pharmacotherapy of hypertension in patients with pre-dialysis chronic kidney disease. 2020 , 21, 1201-1217	1
213	Serum levels of IL-6, IL-8 and IL-10 and risks of end-stage kidney disease and mortality. 2021 , 36, 561-563	3

212	Differential Effects of β -Blockers on Albuminuria in Patients With Type 2 Diabetes. <i>Hypertension</i> , 2005 , 46, 1309-1315	8.5	1
211	Remission of renal disease: recounting the challenge, acquiring the goal. 2002 , 110, 1753-8		56
210	Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). 2006 , 29 Suppl, S1-105		190
209	Association of high blood pressure with renal insufficiency: role of albuminuria, from NHANES, 1999-2006. 2012 , 7, e37837		10
208	Renal function can improve at any stage of chronic kidney disease. 2013 , 8, e81835		27
207	Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial. 2015 , 10, e0125519		5
206	Variability of the Estimated Glomerular Filtration Rate in the First Year after Kidney Transplantation Is an Independent Risk Factor for Poor Renal Allograft Outcomes: A Retrospective Cohort Study. 2016 , 11, e0168337		5
205	Treatment with enalapril and not diltiazem ameliorated progression of chronic kidney disease in rats, and normalized renal AT1 receptor expression as measured with PET imaging. 2017 , 12, e0177451		7
204	Evaluation of Hypertension. 2020 , 19, 8-19		2
203	Fixed-Dose Combination Therapy in Hypertension. 2012 , 19, 51		2
202	Angiotensin II blockade and renal protection. 2013 , 19, 3033-42		53
201	Mineralocorticoid Receptor Antagonists for Nephroprotection: Current Evidence and Future Perspectives. 2018 , 24, 5528-5536		10
200	Implications of the New 2017 American College of Cardiology/American Heart Association Guidelines for Hypertension. 2019 , 67, 399-410		4
199	Risk Factors for the Progression of Pediatric Chronic Kidney Disease-A Single Center Study. 2007 , 11, 239		3
198	Racial and Sex Differences in the Response to First-Line Antihypertensive Therapy. <i>Frontiers in Cardiovascular Medicine</i> , 2020 , 7, 608037	5.4	2
197	Ideal Target Blood Pressure in Hypertension. 2019 , 49, 1002-1009		7
196	RP-HPLC Method for the Determination of Losartan Potassium and Ramipril in Combined Dosage Form. 2010 , 72, 108-11		9
195	Risks of rapid decline renal function in patients with type 2 diabetes. 2014 , 5, 835-46		37

- 194 The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease. **2015**, 6, 1
- 193 Chronic kidney disease at presentation is not an independent risk factor for AIDS-defining events or death in HIV-infected persons. **2013**, 79, 93-100 1
- 192 Mucosal delivery systems of antihypertensive drugs: A practical approach in general practice. **2018**, 162, 71-78 3
- 191 Urgent call for reconsideration of chronic kidney disease. **2012**, 1, 155-9 4
- 190 The 2017 Focused Update of the Guidelines of the Taiwan Society of Cardiology (TSOC) and the Taiwan Hypertension Society (THS) for the Management of Hypertension. **2017**, 33, 213-225 37
- 189 Calcium channel blockers versus other classes of drugs for hypertension. **2021**, 10, CD003654 3
- 188 Hypertensive Kidney Disease. **2022**, 103-129
- 187 Hypertension and Cardiovascular Disease in Patients with Chronic Kidney Disease. **2022**, 281-295 0
- 186 Antihypertensive therapy: Progression of Renal Injury. **2003**, 209-240
- 185 Inhibitors of the RAS: Evidence-Based Medicine. **2004**, 545-592
- 184 Initial Choices in the Treatment of Hypertension. **2005**, 507-511
- 183 A Attitudes Regarding Hypertension Among Older African-American Adults. **2005**, 429-450
- 182 Critical Assessment of Hypertension Guidelines. **2005**, 391-399
- 181 Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). **2006**, 2006, 64-66
- 180 The health consequences in African-Americans of each component of the metabolic syndrome. **2006**, 1, 283-289
- 179 Cardiovascular Disease in Racial and Ethnic Minorities. **2006**, 721-751 0
- 178 Kidney Disease in Hypertension. **2007**, 351-360
- 177 The Heart and the Kidney. **2007**, 2819-2837

176 Treatment of Hypertension in Patients with Renal Disease. **2007**, 647-657

175 Progression of Kidney Failure in Patients with Non-diabetic Chronic Kidney Disease under Combination Therapy in Japan. **2007**, 2, 116-125

174 Design of Outcome Studies. **2007**, 305-315

173 Hypertension in Racial and Ethnic Minorities. **2007**, 707-718

172 Ramipril as a universal oragnoprotector. **2007**, 13, 220-224

171 Prevention of Progressive Renal Failure. **2008**, 699-714

170 Chronic Kidney Disease. **2008**, 287-311

169 Role of Glomerular Pressure in Progression. **2008**, 2537-2561

168 Calcium Channel Blockers. **2008**, 610-619

o

167 Hypertension. **2008**, 145-165

166 Deciding When Blood Pressure Is Too High. **2009**, 73-94

165 Rationale for fixed-dose combination therapy to reach lower blood pressure goals. **2008**, 101, 918-24

1

164 Obesity and the Cardiometabolic Syndrome: Impact on Chronic Kidney Disease and CVD. **2009**, 193-213

163 RENAL INSUFFICIENCY. **2009**, 435-444

162 Antihypertensive Drugs. **2009**, 198-234

161 Hypertension. **2009**, 437-464

160 Chronische Niereninsuffizienz. **2010**, 199-227

159 Microalbuminuria and Kidney Disease: An Evidence-based Perspective. **2010**, 117-130

- 158 Chronic Kidney Disease in the Primary Care Setting: Importance for Estimating Cardiovascular Disease Risk and Use of Appropriate Therapies. **2011**, 165-183
- 157 Hypertension in Chronic Kidney Disease. **2011**, 397-418
- 156 Hypertension. **2011**, 121-140
- 155 Posebne populacije bolesnika - udružna ishemijska bolest srca i hronična bubrežna insuficijencija. **2011**, 30, 181-184
- 154 Antihypertensive Drugs and Their Cardioprotective and Renoprotective Roles in the Prevention and Management of Cardiovascular Disease. **2011**, 161-181
- 153 Hypertension. 227-261
- 152 Perspektivy klinicheskogo primeneniyanovoy fiksirovannoy kombinatsii -preparata Ko-Eksforzh v lecheniiarterial'noy gipertonii. **2011**, 2, 64-71
- 151 Changes of Cytochrome P-450 Isoforms mRNA Expression by Treadmill Exercise in the kidney of Spontaneously Hypertensive Rat. **2011**, 22, 1853-1861
- 150 The role of vasodilating βblockers in patients with complicated hypertension: focus on nebivolol. **2011**, 10, 94-98
- 149 Chronic Kidney Disease. **2012**, 477-497
- 148 Antihypertensive Therapy Benefits: Pleiotropic Versus Blood Pressure-Dependent Mechanisms. **2012**, 249-266
- 147 A Stepped Care Approach to the Management of Chronic Kidney Disease. **2012**, 2205-2239 1
- 146 Hypertension in African Americans. **2013**, 356-364
- 145 Antihypertensive Therapy in Non-Diabetic Chronic Kidney Disease Associated with Proteinuria in Adults. **2013**, 03, 128-134 0
- 144 Hypertension in Chronic Kidney Disease. **2013**, 323-342 1
- 143 Preventive Lessons from Hypertension and Myocardial Infarction: Treating Asymptomatic Individuals to Lower the Risk for Subsequent Cardiovascular Events. **2014**, 229-239
- 142 Hypertension and Chronic Kidney Disease. **2014**, 57-69
- 141 Chronic Kidney Disease and Cardiovascular Risk. **2014**, 49-61

- 140 Introduction of Recent Hypertension Guidelines. **2014**, 87, 127 0
- 139 Chronische nierschade, implementatie richtlijnen en transmurale afstemming. **2014**, 89-95
- 138 Practical Pearls in the Treatment of Hypertension in Blacks. **2015**, 213-232
- 137 Authors' reply: Are we any clearer on the blood pressure targets?. **2014**, 55, 554 1
- 136 Chronic Kidney Disease (CKD) Clinical Trials: A Critical Appraisal. **2015**, 71-91
- 135 Vaskulopathien. **2016**, 355-389
- 134 Blood Pressure Control and Primary Prevention of Stroke: Summary of Clinical Trial Data. **2016**, 39-59
- 133 Progression of Chronic Kidney Disease and Nephroprotective Therapy. **2016**, 1399-1423 0
- 132 Epidemiology of Hypertension in Chronic Kidney Disease. **2016**, 1-13
- 131 Hypertension in Chronic Kidney Disease. **2016**, 1-22
- 130 ANTIHYPERTENSIVE DRUG UTILISATION PATTERN AMONG CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING MAINTENANCE DIALYSIS IN A TERTIARY CARE TEACHING HOSPITAL. **2016**, 5, 3207-3211
- 129 Hypertension in Older Adolescents and Young Adults. **2017**, 1-12
- 128 What should the blood pressure be in patients with chronic kidney disease?. **2017**, 5, 48
- 127 L-Name Hipertansif Ratlarda Ace İhhibitöle Birlikte L-Karnitin ve Co-Enzim Q10 Verilmesinin Total Oksidan ve Antioksidan Dzeyleri izerine Etkileri. 143-151
- 126 Kidney Disease. **2017**, 235-252 1
- 125 Hypertension in Older Adolescents and Young Adults. **2018**, 651-662
- 124 Role of Renin-Angiotensin-Aldosterone System Inhibition in Autosomal Dominant Polycystic Kidney Disease. **2018**, 209-218
- 123 Determinants of Hypertensive Renal Disease and Its Progression. **2018**, 465-478

122 Chronic Kidney Disease. **2018**, 325-339

121 Treatment of Hypertension: A Review. **2019**, 03, 101-123

0

120 CYP2C11 played a significant role in down-regulating rat blood pressure under the challenge of a high-salt diet. **2019**, 7, e6807

2

119 Optimal blood pressure target and measurement in patients with chronic kidney disease. *Korean Journal of Internal Medicine*, **2019**, 34, 1181-1187

2.5 3

118 Achieving blood pressure control targets in hypertensive patients of rural China: A pilot randomized trial.

117 Influence of angiotensin-converting enzyme inhibitor ramipril on indicators of tubular kidney lesion in patients with chronic glomerulonephritis. **2020**, 33, 17-20

116 What are the blood pressure targets for patients with chronic kidney disease?. **2020**, 66, 200-204

115 Blood pressure targets in chronic kidney disease: an update on the evidence. **2020**, 29, 327-332

2

114 Blood Pressure Control among Adult African Chronic Kidney (CKD) Patients: How Close Are We to Target?. **2020**, 10, 50-59

113 Prevalence of Chronic Kidney Disease in Patients with Cardiovascular Disease. **2020**, 10, 227-240

112 Should Estimated Glomerular Filtration Rate Be Adjusted for Race?. **2021**, 10, 1254-1262

111 The effect of renin-angiotensin-aldosterone system blockers on the progression of chronic kidney disease in hypertensive elderly patients without proteinuria: PROERCAN study. Rationale and design. **2020**, 37, 101-107

110 Etiology, Diagnosis, and Management of Chronic Renal Insufficiency in the Aged. **2008**, 429-441

109 Diagnosis and Management of Hypertensive Renal and Renovascular Disease in the Elderly. **2005**, 171-195

108 Hypertension Controversies. **2007**, 137-157

107 Chronische Niereninsuffizienz. **2007**, 197-225

106 More than just hype. **2003**, 168, 1646; author reply 1647-8

105 Executive summary of the African-American Initiative. **2007**, 9, 28

3

104	Hypertension and progression of nephropathy in diabetic and non-diabetic chronic kidney disease patients. 2007 , 11, 72-6		4
103	Cardiovascular disease and African Americans: why determination of race is inadequate for research and practice. <i>Journal of the National Medical Association</i> , 2007 , 99, 686-9	2.3	4
102	Transforming growth factor beta and excess burden of renal disease. 2009 , 120, 61-72		16
101	Role of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension of chronic kidney disease and renoprotection. Study results. 2011 , 15, 27-32		23
100	Renal failure (chronic). 2011 , 2011,		
99	Challenges and scientific considerations in hypertension management reflected in the 2012 recommendations of the Canadian Hypertension Education Program. 2012 , 6, e127-33		1
98	Management of Diabetic Nephropathy in the Elderly: Special Considerations. 2012 , 2,		
97	Hypertension and chronic kidney disease: controversies in pathogenesis and treatment. 2013 , 65, 37-50		13
96	Addressing the global burden of chronic kidney disease through clinical and translational research. 2014 , 125, 229-43; discussion 243-6		81
95	Utilization, Cost, and Affordability of Antihypertensive Therapy in Bulgaria. 2021 , 20, 403-416		
94	APOL1 genotypes: Do they contribute to ethnicity-associated biological health inequalities in pregnancy?. 1753495X2110437		
93	The Implication of Dropping Race from the MDRD Equation to Estimate GFR in an African American-Only Cohort. 2021 , 2021, 1880499		0
92	ANTIHYPERTENSIVE PHARMACOTHERAPY IN HYPERTENSIVE PATIENTS AT A TERTIARY CARE TEACHING HOSPITAL AND MEDICAL COLLEGE IN INDIA. 30-36		
91	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 ,	12.7	0
90	A machine learning pipeline revealing heterogeneous responses to drug perturbations on vascular smooth muscle cell spheroid morphology and formation. 2021 , 11, 23285		3
89	Progression of Chronic Kidney Disease and Nephroprotection in Children. 2021 , 1-22		
88	Hypertension Management in Patients with Chronic Kidney Disease in the Post-SPRINT Era.. 2021 , 19, 19-28		1
87	Blutdruck bei Niereninsuffizienz. 2020 , 24, 355-359		

86	An Analytics Approach to Guide Randomized Controlled Trials in Hypertension Management.	0
85	KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD.. 2022,	1
84	Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021.. 2022, 23, 9	3
83	Hypertension. 2022, 511-528	
82	Calcium channel blockers versus other classes of drugs for hypertension.. 2022, 1, CD003654	0
81	Bluthochdrucktherapie bei Patienten mit CKD. <i>Der Nephrologe</i> , 2022, 17, 17-25	0.1
80	Update in Hypertension.. <i>Medical Clinics of North America</i> , 2022, 106, 259-267	7 0
79	Clinical trials report. Combination drug treatment for hypertension with nondiabetic renal disease. <i>Current Hypertension Reports</i> , 2005, 7, 358-9	4.7
78	Short term outcome of patients attending a renal-immunology clinic in central India.. <i>Journal of Postgraduate Medicine</i> , 2022,	0.8
77	Intensive Systolic Blood Pressure Lowering and Kidney Disease Progression in IgA Nephropathy: A Cohort Study.. <i>Frontiers in Medicine</i> , 2022, 9, 813603	4.9 0
76	New Trends in the Diagnosis and Management of Hypertension.. <i>Cureus</i> , 2022, 14, e22393	1.2
75	Comparison of Aptamer-Based and Antibody-Based Assays for Protein Quantification in Chronic Kidney Disease.. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022,	6.9 2
74	Age-Period-Cohort Analysis of Long Trend of Mortality for Stroke and Subtypes Attributed to High SBP in Chinese Adults.. <i>Frontiers in Neurology</i> , 2022, 13, 710744	4.1 1
73	Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: A systematic review and network meta-analysis.. <i>Journal of Clinical Hypertension</i> , 2022,	2.3
72	Development and Validation of Prediction Models for Hypertensive Nephropathy, the PANDORA Study.. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 794768	5.4
71	Identification of 27 Novel Variants in Genes , and in Lithuanian Families With Alport Syndrome.. <i>Frontiers in Medicine</i> , 2022, 9, 859521	4.9
70	Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial).. <i>Diabetes Research and Clinical Practice</i> , 2022, 185, 109804	7.4 0
69	Short-term Effects of Losartan on Cardiovascular Risk and Allograft Injury Biomarkers in Kidney Transplant Recipients.. <i>Transplantation Proceedings</i> , 2022,	1.1

68	Longitudinal TNFR1 and TNFR2 and Kidney Outcomes: Results from AASK and VA NEPHRON-D.. <i>Journal of the American Society of Nephrology: JASN</i> , 2022 ,	12.7	1
67	Racial Differences in Blood Pressure Control from Users of Antihypertensive Monotherapy: Results from the ELSA-Brasil Study.. <i>Arquivos Brasileiros De Cardiologia</i> , 2022 , 118, 614-622	1.2	0
66	Relationship of indoor solid fuel use for cooking with blood pressure and hypertension among the elderly in China.. <i>Environmental Science and Pollution Research</i> , 2022 , 1	5.1	1
65	Early Identification of Chronic Kidney Disease [A Scoping Review of the Global Populations.. <i>Kidney International Reports</i> , 2022 ,	4.1	0
64	Intensive Blood Pressure Treatment Goals: evidence for cardiovascular protection from observational studies and clinical trials.. <i>American Journal of Hypertension</i> , 2022 ,	2.3	
63	Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs.. <i>Korean Journal of Internal Medicine</i> , 2022 ,	2.5	0
62	It's Not All Even. <i>Physician Assistant Clinics</i> , 2022 , 7, 357-365	0.2	
61	Benefits of more intensive versus less intensive blood pressure control. Updated trial sequential analysis.. <i>European Journal of Internal Medicine</i> , 2022 ,	3.9	2
60	New Aspects in the Management of Hypertension in Patients with Chronic Kidney Disease not on Renal Replacement Therapy.. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021 , 29, 125	2.9	
59	SPRINT Revisited: Updated Results and Implications. <i>Hypertension</i> , 2021 , 78, 1701-1710	8.5	2
58	Presentation_1.PPTX. 2020 ,		
57	Kidney Risk Variants and Proteomics.. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022 ,	6.9	0
56	Tight Blood Pressure Control in Chronic Kidney Disease. <i>Journal of Cardiovascular Development and Disease</i> , 2022 , 9, 139	4.2	1
55	Urinary sulfate, kidney failure, and death in CKD: the African American Study of Kidney Disease and Hypertension. <i>Kidney360</i> , 10.34067/KID.0000322022	1.8	
54	Antihypertensive therapies. 2013 , 224-271		
53	The removal of race from kidney function estimation: Key points for primary providers. <i>Journal of the National Medical Association</i> , 2022 ,	2.3	0
52	Ageing and the Kidneys. 2022 , 787-797		
51	Disease of the Renal Vessels. 2022 , 353-376		

50	Controversies in Hypertension II: the Optimal Target Blood Pressure. <i>American Journal of Medicine</i> , 2022 ,	2.4	
49	Impact of Home Telemonitoring and Management Support on Blood Pressure Control in Nondialysis CKD: A Systematic Review and Meta-Analysis. <i>Canadian Journal of Kidney Health and Disease</i> , 2022 , 9, 205435812211062	2.3	○
48	Hypertension in Chronic Kidney Disease. 2022 , 1-22		
47	Blood pressure and kidney outcomes in patients with severely decreased glomerular filtration rate: a nationwide observational cohort study. <i>Journal of Hypertension</i> , Publish Ahead of Print,	1.9	
46	Actual impact of angiotensin II receptor blocker or calcium channel blocker monotherapy on renal function in real-world patients. <i>Journal of Hypertension</i> , Publish Ahead of Print,	1.9	
45	The impact of pharmacist-led interventions on blood pressure control among patients with chronic kidney disease: A randomized controlled trial. <i>JACCP Journal of the American College of Clinical Pharmacy</i> ,	1.4	
44	Effect of Calcium Channel Blockers versus Diuretics for Hypertension. 2022 , 2022, 1-7		
43	Hypertension Management in Patients with Chronic Kidney Disease. 2022 , 18, 41-49		○
42	Progression of Chronic Kidney Disease and Nephroprotection in Children. 2022 , 1679-1700		○
41	Polypharmacology in Clinical Applications: Cardiovascular Polypharmacology. 2022 , 133-198		○
40	Nefroangioesclerosis: actualizaci3n. 2022 ,		○
39	Considerations for Optimal Blood Pressure Target of Hypertension. Publish Ahead of Print,		○
38	Time to doubling of serum creatinine in patients with diabetes in Ethiopian University Hospital: Retrospective follow-up study. 2022 , 17, e0274495		○
37	Novel antihypertensive agents for resistant hypertension: what does the future hold?.		○
36	Guideline-Directed Medical Therapy Attainment and Outcomes in Dialysis-Requiring Versus Nondialysis Chronic Kidney Disease in the ISCHEMIA-CKD Trial.		○
35	Randomized Controlled Trials on Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease Stages 3B: Are They Robust? A Fragility Index Analysis. 2022 , 11, 6184		○
34	Randomized controlled trials of biomarker targets. 174077452211318		○
33	Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?.		○

- 32 Hypertension. **2022**, 329-353 ○
- 31 Chronic Kidney Disease and Hypertension. **2022**, 573-588 ○
- 30 Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. **2022**, 2022, ○
- 29 The role of blood pressure control in the prevention of cardiorenal disease in patients with chronic kidney disease. ○
- 28 Effects of Bardoxolone Methyl in Alport Syndrome. C.JN.02400222 2
- 27 Renin-angiotensin blocker use is associated with improved cardiovascular mortality in Indian patients with mild-moderate chronic kidney disease findings from the ICKD study. 9, ○
- 26 Analysis of lifestyle modifications and antihypertensive therapy in patients with arterial hypertension and chronic kidney disease (data from the national registry). **2022**, 19, 39-46 ○
- 25 GPR97 deficiency ameliorates renal interstitial fibrosis in mouse hypertensive nephropathy. ○
- 24 Hypertension in Chronic Kidney Disease. **2023**, 477-498 ○
- 23 Blood Pressure Lowering and Microvascular Complications of Diabetes. **2023**, 327-335 ○
- 22 Racial and Ethnic Disparities in Hypertension: Barriers and Opportunities to Improve Blood Pressure Control. **2023**, 25, 17-27 ○
- 21 Which blood pressure threshold indicates a therapeutic benefit for patients with chronic kidney disease?. ○
- 20 Intensive BP Control in Patients with CKD and Risk for Adverse Outcomes. **2023**, Publish Ahead of Print, ○
- 19 Role of hypertension in progression of pediatric CKD. ○
- 18 The global burden of disease attributable to metabolic risks in 204 countries and territories from 1990 to 2019. **2023**, 196, 110260 ○
- 17 Renal Hypertension: Etiology and Management. **2023**, 1337-1362 ○
- 16 Progression of Chronic Kidney Disease and Nephroprotective Therapy. **2023**, 1483-1515 ○
- 15 Body Position and Orthostatic Hypotension in Hypertensive Adults: Results from the Syst-Eur Trial. **2023**, 80, 820-827 ○

- 14 Systolic blood pressure, low-density lipoprotein cholesterol levels, and adverse kidney outcome: results from KNOW-CKD. ○
- 13 When You SPRINT, It's Good to Know the Goal as Well as the Goal Line. **2023**, 34, 359-360 ○
- 12 Dietary Patterns, Apolipoprotein L1 Risk Genotypes, and CKD Outcomes Among Black Adults in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study. **2023**, 5, 100621 ○
- 11 Urine Cell Transcriptomes Implicate Specific Renal Inflammatory Pathways Associated With Difficult-to-Control Hypertension. ○
- 10 Alterations in the Circulating Proteome Associated with Albuminuria. **2023**, Publish Ahead of Print, ○
- 9 Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. **2023**, 388, 969-979 ○
- 8 Hypothetical intervention of targeted systolic blood pressure control of $\leq 120\text{ mmHg}$ on renal prognosis for persons with stage 3&4 chronic kidney disease: an application of parametric g-formula using health checkup data in Japan. ○
- 7 Additive effects of intensive BP control and ACE inhibition on suppression of proteinuria in patients with CKD. ○
- 6 Association of blood pressure and hyperuricemia with proteinuria and reduced renal function in the general population. ○
- 5 Blood Pressure in CKD. **2023**, 115-129 ○
- 4 Blood pressure status affects atrial fibrillation in diabetic end-stage renal disease. **2023**, 18, e0283875 ○
- 3 Diabetic Kidney Disease. **2023**, ○
- 2 Treating chronic kidney disease to reduce cardiovascular risk. **2023**, 25, B50-B54 ○
- 1 Should we discontinue RAS-inhibitor therapy in patients with advanced CKD?. 1-4 ○